Enhancement of Carrimycin Production Via Traditional Mutagenesis with Metabolic Engineering in Streptomyces Spiramyceticus 54IA

Enhancement of Carrimycin Production Via Traditional Mutagenesis with Metabolic Engineering in Streptomyces Spiramyceticus 54IA | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Enhancement of Carrimycin Production Via Traditional Mutagenesis with Metabolic Engineering in Streptomyces Spiramyceticus 54IA Kemeng Li, Jianlu Dai, Juanjuan Liu, Tianyi Hao, Weiqing He This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-1204059/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Background: Carrimycin is a new approved class I antibiotic in China. The novel carrimycin producing strain, Streptomyces spiramyceticus 54IA, was constructed by CRISPR-Cas9 editing system without insertion of antibiotics resistant gene. The problem of low yield limits this strain in large scale fermentation. In this study, the carrimycin production was significantly improved by strain mutagenesis coupled metabolic engineering. Results: The sspD gene is responsible for degradation of triacylglycerol to provide precursors of the polyketide biosynthesis. The extra sspD gene controlled by the promoters of pks and bsm42 genes could moderately enhance carrimycin production. The Bsm42 was identified to play a pathway-specific positive regulator for carrimycin biosynthesis. Due to production of carrimycin significantly enhanced by bsm42 overexpression, the two different length promoters of bsm42 individually ligated with two reporter genes were used to monitor bsm42 expression for screening the higher carrimycin production mutants treated by plasma and ultraviolet. 47% of the 608 selected mutants had higher fermentation titer than the starting strain. The shorter promoter of bsm42 displayed more appropriate for selection of the carrimycin production improved mutants. The F2R-15 mutant had highest titer (1010±30 μg/mL), which was about 9 times higher than that of 54IA strain. Comparative analysis of transcriptome profiles of F2R-15 mutant and 54IA strains found 158 differential expression genes with more than 2 fold-changes. The up-regulated genes were associated with macrolide precursor biosynthesis, macrolide-inactivation, antibiotics transporter, oxidative phosphorylation; while the most down-regulated genes were referring to the primary metabolites synthetic genes and biosynthetic genes of other secondary metabolites. Conclusion: These results suggested that manipulation of the positive regulatory gene bsm42 and traditional mutagenesis coupled with reporter-guided mutant selection method facilitated selection of carrimycin high-yielding mutants. carrimycin Streptomyces spiramyceticus 54IA positive regulator reporter gene Figures Figure 1 Figure 2 Figure 3 Background Carrimycin, also known as bitespiramycin and shengjimycin, is a new, hybrid macrolide antibiotic approved by the China National Medical Products Administration in 2019. It is produced by recombinant Streptomyces spiramyceticus , which harbors a 4″- O -isovaleryltransferase gene ( ist ) from Streptomyces thermotolerans [1, 2]. Carrimycin mainly consisted of isovalerylspiramycins I, II, III and contained trace amount of other 4″- O -acylspiramycin components [3]. Compared to spiramycin, carrimycin has a longer half-life, higher potency, and greater tissue penetration [4, 5]; it shows potent inhibition to the G + pathogens, and recently was identified as an antiviral agent against a broad-spectrum of human coronaviruses, including the SARS-Cov-2 virus [6]. The carrimycin engineering strain, Streptomyces spiramyceticus WSJ-195 [7], was resistant to apramycin, thiostreptomycin and kanamycin, and it is difficult to perform directed genetic manipulation for this strain using the existing Streptomyces plasmids. So, a novel carrimycin-producing strain ( Streptomyces spiramyceticus 54IA) without resistant genes insertion into the genome was constructed by using CRISPR-Cas9 editing system [8]. The titer of carrimycin was improved through the ribosome engineering, but it was far from the requirement in the scale-up fermentation. Many efforts have been made to improve the production of carrimycin in Streptomyces spiramyceticus WSJ−195 in recent years, including traditional random mutagenesis [9, 10], medium optimization [11], exogenous feeding strategies [12, 13], fermentation process control [14], and genetic engineering [15]. Among these approaches, traditional mutagenesis is a powerful and easily operated method for strain improvement in Streptomyces , especially for microbes with less understanding of genomic information and metabolic mechanisms. Although the isovalerylspiramycins I (one component of carrimycin) high-producing strains have been developed with the composite mutagenesis of Plasma and UV [16], it is definitely laborious and time-consuming to improve carrimycin production by just relying on random mutagenesis and ordinary screen methods. Thus, traditional mutagenesis should combine with rational metabolic engineering strategies to shorten the process of strain breeding. Metabolic engineering strategies have been widely used in the improvement of secondary metabolites in microbes, especially for the production of antibiotics. Currently, the improved production of antibiotics through metabolic engineering mainly focuses on investigation of regulatory genes [17], improvement of precursor supply [18, 19], and comparative metabolomics profiling analysis [20, 21]. Among those strategies, enhanced precursor supply has been indicated to be a direct way to increase the accumulation of desired natural products. For example, the increased supply of propionyl-CoA carboxylase along with the addition of propionate was found to be an effective way to increase the concentration of intracellular methylmalonyl-CoA for rapamycin biosynthesis in S. hygroscopicus [22]. Spiramycin’s structural backbone is a polyketide, putative platenolide I including ethylmalonyl-CoA, methylmalonyl-CoA and methoxymalonyl-CoA, which depends on polyketides synthase (PKS) and malonyl-CoA for its biochemical composition [23]. Wang et al [24] applied multi-omics to reveal that intracellular triacylglycerols (TAGs) pool as an intracellular carbon source for polyketide biosynthesis during stationary phase, and the mobilization of cellular TAGs enables carbon flux to be redirected to polyketide biosynthesis. They devised a new dynamic degradation of TAG (ddTAG) strategy that increases polyketide titers and applied ddTAG in four Streptomyces species to increase yields of actinorhodin (Act), jadomycin B, oxytetracycline and avermectin B1a. The sco6196 is the key gene involved in degradation of TAG in S. coelicolor . Given that accumulation of a TAG pool is widespread in actinomycetes [25]. The strategy of TAG appropriately degradation can be also widely used for improvement of polyketide antibiotics biosynthesis. The positive regulatory genes of spiramycin biosynthesis, srm22 and srm40 , also were identified in this gene cluster. Srm40 is a pathway-specific activator in spiramycin biosynthesis, and Srm22 is required for srm40 expression [26]. The bsm23 and bsm42 genes in Streptomyces spiramyceticus , homologous with srm22 and srm40 , also play the positive regulatory genes involved in spiramycin biosynthesis [27]. The Bsm42 plays the role in the activation of spiramycin biosynthesis, and its overexpression can improve the yield of spiramycin. However, we discovered that Bsm23 inhibited spiramycin production at high expression level although it was a necessary regulatory gene for spiramycin biosynthesis. The expression level of the transcriptional activators can play as an indicator for high production of target metabolite. A double reporter-guided mutant selection method has been developed to facilitate selection of clavulanic acid high-yield mutants [28]. Carrimycin is a new potent drug for anti-infection and had antiviral activity. We constructed a new resistant marker-free strain Streptomyces spiramyceticus 54IA by CRISPR-Cas9 editing system. But the carrimycin production of 54IA is far lower than that of the WSJ-195 strain. In this study, the carrimycin production was improved by increasing expression of sspD , homologous to sco6196 , through introducing extra sspD copy under the control of the promoter of carrimycin biosynthetic genes. The more concentration of SspD at appropriate time means the more the precursors degraded from of TAG for carrimycin biosynthesis. Furthermore, investigation and manipulation of the positive regulator is another effective way to enhance the yield of carrimycin. Results The analysis of SspD, homolog of SCO6196 , in streptomyces spiramyceticus 54IA SCO6196 is AMP-binding domain-containing protein to activate fatty acids by binding to coenzyme A in the Streptomyces coelicolor A3 (2). It can channel carbon flux from both intracellular TAGs and extracellular substrates into polyketide biosynthesis. SspD in Streptomyces spiramyceticus 54IA (533 amino acid residues) had high sequence similarity (80% identity and 88% similarity) to the SCO6196 from Streptomyces coelicolor A3 (2). However, its upstream and downstream genes display significantly difference with that of sco6196 (Figure 1A). In order to gain the improvement of expressing sspD to supply more precursors for carrimycin biosynthesis, the extra constructed sspD gene was driven by the P pks or P bsm42 promoter in the carrimycin biosynthetic gene cluster, both of which were activated during the stationary phase of the host strain. Plasmids pSET- Ppks-sspD and pSET- Pbsm42-sspD were thus constructed (Figure 1B) and used to transform 54IA strain to obtain strain 54IA:: Ppks- sspD and 54IA:: Pbsm42- sspD . Table 1 Fermentation titer of the wild-type strain and transformants Strains Fermentation titer（μg/mL） Concentration of isovalerylspiramycins （μg/mL） 54IA 115±13.96 56.17±4.31 54IA:: Ppks-sspD 253±12.75 93.63±6.63 54IA:: Pbsm42-sspD 187±9.42 79.74±3.96 54IA:: kasOp* - bsm42 964±34.87 325.04±19.45 54IA:: kasOp* - bsm23 276±18.55 65.75±8.21 Date are means ± SE of three independent biological replicates 54IA:: Ppks- sspD and 54IA:: Pbsm42- sspD showed higher titer than that of the original strain 54IA. As shown in Table 1, the titer of 54IA:: Ppks- sspD and 54IA:: Pbsm42- sspD reached 253±12.75 μg/mL and 187±9.42 μg/mL, which are 2.2 and 1.6 times higher than that of 54IA, respectively. In order to calculate the yield of the isovalerylspiramycins, the three main active components of carrimycin, the fermentation broth extractions of the strains were analyzed by HPLC. Based on the standard curves of carrimycin, the isovalerylspiramycins yield of in strain 54IA ::Ppks-sspD (93.63±6.63 μg/mL) and 54IA:: Pbsm42- sspD (79.74 μg/mL) (Table 1) were significantly increased than that of 54IA (56.17±4.31 μg/mL). The results suggest that improved sspD expression at suitable time controlled by the appropriate promoter could effectively enhance the yield of carrimycin in 54IA strain. Enhancement of carrimycin production by overexpression of Bsm23 and Bsm42 positive transcription regulators It has been reported that Bsm23 and Bsm42 are two positive regulators of the spiramycin biosynthesis. To investigate the performance of Bsm23 and Bsm42 in the regulation of carrimycin biosynthesis, bsm23 and bsm4 2 were both overexpressed in 54IA strain. Plasmid pSET- kasOp*-bsm23 containing bsm23 assembled with kasOp* promoter was constructed, and plasmid pSET- kasOp*-bsm42 contained bsm42 which was also driven by kasOp* promoter (Figure 1B). The two recombinant plasmids were then transferred into 54IA to give strain 54IA:: kasOp*-bsm23 and 54IA:: kasOp*-bsm42 . In Table 1, the results showed that the titer of strain 54IA:: kasOp*-bsm42 reached as high as 964±34.87 μg/mL, which was 7.4 times higher than that of the original strain 54IA. Meanwhile, its isovalerylspiramycins yield could improve to 325.04±19.45 μg/mL, about 5.8 fold higher than that of 54IA. In contrast, the fermentation titer of strain 54IA:: kasOp*-bsm23 was moderately improved 2.4 times than that of 54IA, but the isovalerylspiramycins production was similar with that of 54IA. Therefore, Bsm42 was the pathway-specific positive activator for carrimycin biosynthesis. So, the improved expression level of bsm42 could play as an indicator for high production of carrimycin in 54IA strain. Double reporter plasmid s for efficient screening for carrimycin high-yield strain Similar to other pathway-specific positive activator, the promoter region of bsm42 could play a direct target for variety of regulatory proteins. We attempt to adjust the expression of bsm42 through mutagenesis method combining with a reporter system to serve as a screening indicator. By protoplast transformation methods, the reporter plasmids pDR-42F1R and pDR-42F2R were transduced into 54IA to obtain the F1R and F2R transformants, respectively. It was found that the wild type strain 54IA could normally grow below 2 μg/mL of kanamycin (Km), however the F1R and F2R could maximally tolerate Km at 60 μg/mL. About 1×10 5 spores of F1R and F2R were separately treated with UV and plasma, followed by spreading spores on greater than or equal to 60 μg/mL of Km. The hundreds of mutants grew out for 7 days of incubation, and then the selection plates were sprayed with catechol. 608 yellow-colored mutants were randomly picked for carrimycin titer measurement. The 286 mutants (47%) produced statistically higher carrimycin yield than the starting strain 54IA containing the pDR2 plasmid (Figure 2 and Table 2). The titers of positive F1R transformants (Figure 2A) were much lower than that of the selected F2R tranformants. Among F2R tranformants tested in Figure 2B, F2R-15 strain with the 200 μg/mL of Km resistance had the highest titer, reaching at a concentration of 1010±30 μg/mL. Table 2 Positive rates of different F1R and F2R mutant pools Mutant (Km μg/mL) The number of positive strain/total Positive rate F1R (60) 71/147 48% F2R (90) 99/111 89% F2R (150) 87/174 50% F2R (200) 18/89 20% F2R (300) 11/87 13% Total 286/608 47% As shown in Figure 2C, only a few of F1R mutant colonies (Figure. 2C-a) was visually observable yellow color appeared on the lawns, but most of F2R mutant colonies (Figure 2C-b) displayed the significant yellow color. The XylE activities were tested in the highest yield mutants of F1R-4 and F2R-15 (Fig. 2C-c). When sprayed with substrate catechol, the colonies of F2R-15 displayed bright yellow color, at the same time the colonies of F1R-4 showed weak yellow color, while there was no visible yellow color appeared on the lawns of the starting strain 54I-A. Differentially expressed genes between the high-yield strain F2R-15 and 54IA Comparative analysis of transcriptome profiles from RNA-seq of the F2R-15 mutant and 54IA strains found 44 genes with obvious differences in expression, including 20 significantly up-regulated and 24 down-regulated genes (Table 3). The up-regulated genes are associated with carrimycin biosynthetic precursor, macrolide-inactivation, antibiotics transporter, oxidative phosphorylation, two sigma factors and three regulators. The improved genes of ID-6064 and ID-203 are related to the generation of acyl-CoA and Isovaleryl-CoA, which are the important building blocks of carrimycin biosynthesis. Gene of ID-803, macrolide-inactivating glycosyltransferase gene, could play an important role in self-protection to macrolide antibiotic inhibition. There are 7 enhanced expression genes involved in transporter system, especially the response to antibiotic. In addition, some increased genes referring to oxidative phosphorylation might provide more energy for the secondary metabolism. The improvement of sigma factors and three regulatory genes may be directly or indirectly involved in regulating the biosynthesis of carrimycin. The most of down-regulated genes were attributed to 10 secondary metabolites gene clusters referring to the biosynthesis of siderphore, terpene, lassopeptide, feglymycin, ectoine and some t1pks - nrps compounds. Strangely, the deoxysugar biosynthetic genes of carrimycin in F2R-15 mutant also showed lower expression level than that in 54IA. As for genes in synthesis and metabolism of bio-macromolecules, some important genes involved in metabolism of amino acids and nucleotides were increased, however, the key biosynthetic genes of the two primary metabolites were decreased. These results are consistent with the general knowledge that the secondary metabolism initiation would inhibit the primary metabolism. Table 3 Differentially expressed genes between the F2R-15 mutant and 54IA ID Gene description Regulation Fold change Pathway description Precursor biosynthesis 6064 pyruvate dehydrogenase E1 component subunit alpha UP 6.34 Glycolysis, acyl-CoA biosynthesis 203 DNA alkylation response protein, UP 2.22 Isovaleryl-CoA dehydrogenase activity, the leucine degradation pathway Macrolide-inactivating 803 macrolide-inactivating glycosyltransferase UP 3.68 Response to macrolide antibiotic Transporter 2176 ABC transporter permease UP 5.17 Efflux transmembrane transporter activity 5715 Esterase UP 4.49 ATPase activity, glycine betaine transport 711 ATP-binding protein DrrA UP 4.43 Daunorubicin resistance ABC transporter 696 ABC-F family protein UP 3.76 ATPase activity, response to antibiotic 518 MFS transporter UP 2.91 Sporulation 1243 Efflux RND transporter permease subunit UP 2.58 Transmembrane transporter activity, response to antibiotic 6822 ABC transporter, srmB ( bsm25 ) UP 2.00 ATPase activity, response to antibiotic Oxidative phosphorylation 5654 NADH-quinone oxidoreductase subunit L UP 5.64 Oxidative phosphorylation 2106 NADH-quinone oxidoreductase subunit M UP 5.50 5817 NADH-quinone oxidoreductase subunit L UP 4.38 84 NADH-quinone oxidoreductase subunit G UP 2.80 Sigma factor 1068 SigE family RNA polymerase sigma factor UP 2.79 DNA-binding transcription factor activity 699 Sigma-70 family RNA polymerase sigma factor UP 2.55 DNA-binding transcription factor activity Regulator 2796 VWA domain-containing protein UP 6.11 ATPase activity, signal transduction 1928 AfsR family transcriptional regulator UP 4.56 Regulation of transcription (Hyphal growth) 709 Helix-turn-helix transcriptional regulato UP 2.05 Phosphorelay signal transduction system Amino acid metabolism 1738 4-hydroxyphenylpyruvate dioxygenase UP 5.13 Tyrosine and phenylalanine metabolism 2137 glutamine synthetase DOWN 5.81 Glutamine biosynthetic process 827 glutamate synthase large subunit DOWN 3.48 Glutamate biosynthetic process 434 3-isopropylmalate dehydratase DOWN 2.83 Valine, leucine and isoleucine biosynthesis Nucleotide metabolism 357 purine-nucleoside phosphorylase DOWN 6.49 Purine metabolism, Pyrimidine metabolism 955 adenosine deaminase, DOWN 5.00 Nucleotide metabolic process Secondary metabolites gene clusters 1832 IucA/IucC family siderophore biosynthesis protein DOWN 8.33 Desferrioxamine B biosynthetic gene cluster ( Siderophore) 1546 ABC transporter substrate-binding protein DOWN 7.69 2436 aspartate aminotransferase family protein DOWN 5.92 472 IucA/IucC family protein DOWN 7.30 Kanamycin biosynthetic gene cluster 730 iron chelate uptake ABC transporter family permease subunit DOWN 4.55 siderophore biosynthetic gene cluster 1398 serine hydroxymethyltransferase DOWN 3.02 ectoine-butyrolactone biosynthetic gene cluster 503 ABC transporter permease subunit DOWN 2.75 422 purine permease DOWN 3.83 t1pks-nrps metabolite biosynthetic gene cluster 1820 VWA domain-containing protein DOWN 2.56 16 NDP-aminohexose N-dimethyltransferase ( bsm22 ) DOWN 3.27 Deoxysugar biosynthesis of spiramycin 92 NDP-hexose dehydratase ( bsm26 ) DOWN 2.76 74 GTPase ( bsm27 ) DOWN 2.39 18 glycosyltransferase, bsm28 -35 DOWN 2.26 530 DUF350 domain-containing protein DOWN 3.22 Terpene biosynthetic gene cluster 1046 iron-containing alcohol dehydrogenase family protein DOWN 2.04 873 diaminobutyrate--2-oxoglutarate aminotransferase DOWN 2.98 Ectoine biosynthetic gene cluster 87 peptide-N4-asparagine amidase A DOWN 2.83 Feglymycin biosynthetic gene cluster 857 AAA family ATPase DOWN 2.24 ladderane-nrps biosynthetic gene cluster 1704 acetylornithine transaminase DOWN 2.10 Lassopeptide biosynthetic gene cluster The expressions of bsm23 (ID-60), bsm42 (ID-834) and the major up-regulated genes were further validated repeatedly by qPCR (Figure 3). The results showed that the expression level of these up-regulated genes were essentially in agreement with that of trancriptome profiles, only gene 6064, 2176 and 2796 showed much higher expression level. However, the bsm25 (ID-6822), bsm42 (ID-834) and bsm23 (ID-60) located in carrimycin biosynthetic gene cluster had similar expression level between the F2R-15 mutant and 54IA starting strains. Discussion In this article, we explored the feasibility of increasing sspD expression and overexpression of positive transcriptional regulators, bsm23 and bsm42 , for improvement of the carrimycin production in the 54IA strain. The production of carrimycin was moderately increased in the plasmids inserted strain containing the sspD gene under control of the pks or bsm42 promoters. The SspD, SCO6196 homolog, was considered to involve in degradation of TAG to produce the synthetic substrates for carrimycin biosynthesis in 54IA strain. The extra sspD gene copy was designed to expression at the starting period of carrimycin biosynthesis to increase substrate supply for PKS assemble line. This strategy just moderately improved carrimycin biosynthesis probably due to insufficient Ssp improved expression on the control of the pks or bsm42 promoter in 54IA strain. Generally, the antibiotic production is stringently and elaborately regulated by pyramidal transcriptional regulatory cascades, including signaling pathways, global regulators, pathway-specific regulator, and feedback regulation [29]. Combination of different strategies to manipulate regulatory genes can achieve higher antibiotic production in both the native and/or heterologous host. There are many reports proved that overexpression of pathway specific positive regulators can improve the production of antibiotics, such as TylS or (especially) TylR for Tylosin [30], ToyA for toyocamycin biosynthesis [31], SlnR modulated salinomycin biosynthesis [32], and so on. In this study, the Bsm42 plays the similar role in carrimycin biosynthesis, and its overexpression can significantly enhance the yield of carrimycin. Bsm23, however, is also a necessary regulator for carrimycin biosynthesis, but its higher expression cannot significantly enhance the antibiotics yield. The expression level of positive regulator is not always related to the production of antibiotic. These positive regulators also emerged in other antibiotics producing strain. For example, overexpression of milR with a strong constitutive promoter led to decreasing of milbemycin production in S. bingchenggensis [33]. In conclusion, the threshold of the over-expressed regulator was a key point to determine the production of antibiotic. In view of the production of carrimycin correlated with the level of the bsm42 expression, the two different length of promoter of bsm42 was ligated to two reporter genes acting as indicator for screening carrimycin enhanced mutants. In our previous work, a stable isovalerylspiramycin I high-producing strain yielding 2000 μg/mL was obtained though atmospheric and room temperature plasma mutagenesis combined ultraviolet radiation [34]. In this study, this mutagenesis method was used to treat the 54IA containing the reporter plasmids. The bsm42 promoter combined with two reporter genes is efficient selective marker for screening high production of carrimycin through Km resistant and color changes in mutants. The results demonstrated that the shorter promoter of the bsm42 was more suitable for selection of the carrimycin high-yield strains. The efficiently selected strain F2R-15 produced carrimycin at a concentration of 1010±30 μg/mL, which was about 9 times higher than that of the original strain 54IA. The F2R-15 was selected from the plate of Km at 200 μg/mL, but not from the higher resistant concentration of Km. These results suggested the continuous high expression of bsm42 was not always benefit for carrimycin biosynthesis. The up-regulated genes in transciptome profiles of F2R-15 strain and 54IA were related to the macrolide resistant, transport, biosynthetic precursors from TCA or amino acid catabolism. The feedback regulation is often brought by antibiotic to coordinate antibiotic production and transport. Evidences have shown that antibiotic, as ligand for proper regulator, affects the final production in Streptomyces . The expression of antibiotic biosynthetic genes was modulated by the RedZ and undecylprodigiosin complex [35]. The activity of AtrA, which regulates primary and secondary metabolism, is reduced by lidamycin of Streptomyces globisporus and actinorhodin (ACT) of S. coelicolor [36]. Export of antibiotic is important for the producer to reduce the intracellular antibiotic concentration, which can relieve self-toxicity. In Amycolatopsis mediterranei , Δ rifQ mutant brought overexpression of RifP. The accelerated export of rifamycin may reduce the intracellular rifamycin concentration, relieve other possible feedback inhibition of rifamycin biosynthesis and finally lead to more than two-fold improvement of rifamycin B production [37]. Overexpression of DrrC, which provide self-resistance to DNR and DXR, achieved 5.1-fold increase in DXR production in S. peucetius ATCC 27952 [38]. Transporters enhance the efflux of the self-produced antibiotics, which can be an important strategy for self-protection from self-toxicity. The down-regulated genes were mainly located in the other secondary metabolites biosynthetic gene clusters, which might reduce competition for biosynthetic substrates and energy of carrimycin. The decreased genes involved in 10 secondary metabolites gene clusters for the biosynthesis of siderphore, terpene, lassopeptide, feglymycin, ectoine and some t1pks-nrps compounds. However, the most of carrimycin biosynthetic genes in F2R-15 were a little higher expression level than 54IA starting strain, and even the deoxysugar biosynthetic genes were decreased expression. The possible reason is the inappropriate harvesting time of the strains in which production of the carrimycin starts to decline. The above data showed that manipulation of regulatory cascades can be an efficient way to enhance the production of antibiotic. It is obvious that the balance and synergy between primary and secondary metabolism is very important for the overproduction of antibiotic. Rewiring regulatory network combined with metabolic engineering will be a more powerful way to enhance the production of antibiotic in Streptomyces [39]. On the basis of understanding the regulation of antibiotic biosynthesis, rewiring the regulatory network is much more efficient to optimize antibiotic producers than the classical random mutagenesis methods. Material and methods Strains, plasmids, culture conditions and primers All strains and plasmids used in this study are listed in Table S1. The original strain Streptomyces spiramyceticus 54IA was generated from S . spiramyceticus 1941 by inserting ist and acyB2 genes into the downstream of the spiramycin gene cluster [8]. The slant/plate medium, seed medium, and culture conditions for S . spiramyceticus were prepared according to previously described methods [39]. Streptomyces strains were cultivated at 28°C for 120 h in soluble fermentation medium for isolation of total RNA. Soluble fermentation medium (per 100 mL) contained: dextrin, 5.0 g; NaCl, 1g; MgSO 4 , 0.55 g; CaCO 3 , 0.5g; NH 4 NO 3 , 0.7g, KH 2 PO 4 , 0.065 g; ZnSO 4 •7H 2 O 0.01g; CoCl 2 , 5´10 -5 g; with pH adjusted to 7.2 before autoclaving. The primers used are listed in Table S2. DNA isolation, manipulation, sequencing, and bioinformatics analysis Routine DNA manipulation with E. coli and recombinant DNA techniques in Streptomyces species were performed as described previously [40]. Routine DNA sequencing was carried out by The Beijing Ruibiotech (Beijing, China). Primers were synthesized by Sangong (Shanghai, China). Protein secondary structure predictions were performed using the NCBI BLAST program (https://blast.ncbi.nlm.nih.gov/Blast.cgi). The multiple sequence alignments and homology comparisons were performed using Clustal W and BLAST software. Genetic manipulation All plasmids constructed in this study were introduced into S. spiramyceticus 54IA according to the PEG-assisted protoplast transformation method reported previously [41]. To investigate the availability of sco6196 for improving carrimycin biosynthesis in S. spiramyceticus 54IA, the plasmids, pSET- Ppks - sspD and pSET- Pbsm42 - sspD , were constructed to increase the expression of sspD under the control of Ppks and Pbsm42 promoter, respectively. The sspD gene was amplified using primers sspD -F/ sspD -R from the genomic DNA of Streptomyces spiramyceticus . The Ppks and Pbsm42 promoter were amplified using primers Ppks -F/ Ppks -R and Pbsm42 -F/ Pbsm42 -R from the genomic DNA of S. spiramyceticus 54IA. The fragments containing promoter P pks or Pbsm42 with sspD gene were inserted into the Bam HI/ Xba I sites of pSET152 to obtain the resultant plasmids p SET- Ppks - sspD and pSET- Pbsm42 - sspD . To confirm that the positive regulatory gene bsm23 and bsm42 can improve the carrimycin production， bsm23 and bsm42 were amplified by the primers from the genomic DNA of S . spiramyceticus 54IA, and then inserted into Nde I/ Xba I sites of pSET152, under the control of the constitutive promoter kasOp * to get the plasmids pSET- kasOp *-bsm23 and pSET- kasOp *-bsm42 . The construction of x ylE and n eo double-reporter genes controlled by promoters of bsm42 The promoter of bsm42 could play the indicator for enhanced carrimycin biosynthesis. The 300 bp promoter of bsm42 was amplified by the primer Pbsm42 -F1 and Pbsm42 -R, and the primer Pbsm42 -F2 and Pbsm42 -R for the 200 bp length promoter of bsm42 . The two promoter fragments were digested by Not I, then ligated into the upstream of the two reporter genes neo (kanamycin resistance gene) and xylE gene at the pDR2 vector to obtain pDR-42F1R and pDR-42F2R plasmids. The neo was used to ensure the basic selection efficiency while xylE was used to detect target over-expression and visually display the over-expression differences among mutants. The activity of XylE could be detected by spraying catechol on colonies in a selection plate or quantitatively measured in cell-free extract [28]. pDR-42F1R and pDR-42F2R plasmids were individually transduced into the 54IA strain to obtain the resultant strains S. spiramyceticus F1R and F2R. The 54IA strain containing pDR2 was as the control strain. Streptomyces spiramyceticus F 1 R and F 2 R mutated by UV and plasma The lethality rates of S . spiramyceticus F1R and F2R in five different UV treating times were investigated. After treating for 60, 75 and 90 seconds in the UV, the lethality rates of the F2R spores increase to 74.43%, 79.15%, 95.00% respectively, and the lethality rates of the F1R spores could reach 55.48%, 67.77%, 91.54% respectively. As a result, to obtain the desirable lethality rates the exposure time employed in this study were 75-90 s for F1R and 60-90 s for F2R. Quantitative analysis of carrrimycin bioproduction using Streptomyces spiramyceticus 54IA and mutant s S . spiramyceticus 54IA and mutants were grown on agar plates for 7 d at 30 °C. The spores were inoculated into 50 mL fermentation medium in an Erlenmeyer flask (250 mL) and incubated at 28°C and 200 rpm for 7 days. To obtain statistically significant results, three independent strains were selected and fermentations were repeated at least three times independently. The resulting fermentation broth was extracted with ethyl acetate (100 mL), and the solvent was removed in vacuum. The extracts were dissolved in 1 mL CH 3 OH and centrifuged at 13,000g for 10 min, and 10 μL of supernatant was subjected to HPLC analysis following the previously described system [15]. In order to calculate the yields of carrimycin in the mutants and the starting strain 54IA, a quantitative curve was established based on the relationship of integral area and the weight of carrimycin. To quantitatively analyze carrimycin titers in the plasmids transduced strains and that of the original strain, extracts of the mutant strains were diluted 10 times and then subjected to HPLC alongside analogously prepared WT-derived extract. The titers of carrimycin in different strains were calculated based on the established standard carrimycin curve. The t-test was used in the quantitative calculation of carrimycin titers in different strains. Transcriptome analysis and quantitative real-time PCR of s treptomyces spiramyceticus 54IA-2 and mutant strains S. spiramyceticus 54IA and F2R-15 incubated for 120h in soluble fermentation medium were harvested and flash-frozen in liquid N 2 . Frozen mycelia pellets were ground into a fine powder by using a pestle and a mortar, and total RNA was extracted using an RNAprep pure Micro Kit (TIANGEN) according to the manufacturer's instructions. Contaminating chromosomal DNA in the RNA samples was eliminated by treating with DNase I (Promega). The quantity and quality of RNA samples were assessed by measuring the A 260 and A 280 of the samples using Nanodrop (DeNovix), and the integrity of the purified RNA samples was determined by denaturing agarose gel electrophoresis. The transcriptome analysis was performed by OE Biotech (Shanghai, People’s Republic China). P value 2 set as the threshold for significantly differential expression. Genes with more than 2-fold change and P value <0.05 were defined as significantly regulated genes. Quantitative real-time PCR was performed on a Light Cycler 96 (Roche) with FastStart Essential DNA Green Master (Roche). All qPCR gene-specific primers were designed to produce ∼150 bp long amplicons and all reactions were performed in triplicate for three different samples using gene specific primers (Table S3). The 16S RNA gene from S. spiramyceticus 54IA was used as the internal control to normalize samples. PCR program: 96 °C 1 min (96 °C 30 s, 61 °C 30 s, 72°C 1 min) 40 cycles, 72 °C 10 min. Melting-curve analysis was performed to check the specificity of PCR amplification. Melting-curve analysis was performed to check the specificity of PCR amplification. Cycle threshold (Ct) values were obtained from the exponential phase of PCR amplification and genes expression was normalized against the genes expression of 16S RNA to generate a ΔCt value (Ct of target gene–Ct of endogenous control). The change in the genes’ expression was calculated using 2 −ΔΔCt method. Statistics Each experiment was replicated three times, with the error bars showing the standard deviations (SDs). To compare the difference between the test and control data, P values were calculated by Student’s t test ( P < 0.001). The fragment of sco6196 cloned from s treptomyces spiramyceticus 54IA has been deposited in GenBank with the Accession OL616099. Declarations Acknowledgements The authors acknowledge Prof. Weishan Wang for providing pDR2 plasmid. Availability of data and materials Not applicable. Funding CAMS Innovation Fund for Medical Sciences (2021-1-I2M-028), the National Natural Science Foundation of China (No. 82073900, 81773617), Opening Foundation of State Key Laboratory of Bioactive Substance and Function of Natural Medicines (GTZK202103). Authors’ Contributions WQH and TYH conceived the work and drafted the manuscript. KML and JLD, equally to this study, performed experiments and analyzed data. JJL participated in the experiment and collected the data. TYH and WQH wrote and revised the manuscript. All authors read and approved the final manuscript. Correspondent authors Correspondence to Tianyi Hao or Weiqing He. Ethics approval and consent to participate Not applicable Consent for publication Not applicable. Competing interest The authors declare that they have no competing interest. References Shang G, Dai J, Wang Y. Construction and physiological studies on a stable bioengineered strain of shengjimycin. J Antibiot (Tokyo). 2001;54:66–73. Epp JK, Huber ML, Turner JR, Goodson T, Schoner BE. Production of a hybrid macrolide antibiotic in Streptomyces ambofaciens and Streptomyces lividans by introduction of a cloned carbomycin biosynthetic gene from Streptomyces thermotolerans . Gene. 1989;85(2):293–301. Sun CH, Jiang W, Huang J, Jin WZ, Wang YG. Shengjimycins: a group of hybrid antibiotics, 4”-acylspiramycins. Actinomycetologica. 1999;13(2):120–125. Shi XG, Sun YM, Zhang YF, Zhong DF. Tissue distribution of bitespiramycin and spiramycin in rats. Acta Pharmacol Sin. 2004;25(11):1396–401. Shi XG, Fawcett JP, Chen XY, Zhong DF. Structural identification of bitespiramycin metabolites in rat: A single oral dose study. Xenobiotica. 2005;35 (4): 343–358. Yan H, Sun J, Wang K, Wang H, Wu S, Bao L, He W, Wang D, Zhu A, Zhang T, Gao R, Dong B, Li J, Yang L, Zhong M, Lv Q, Qin F, Zhuang Z, Huang X, Yang X, Li Y, Che Y, Jiang J.Repurposing CFDA-approved drug carrimycin as an antiviral agent against human coronaviruses, including the currently pandemic SARS-CoV-2. Acta Pharm Sin B. 2021; 11(9):2850–2858. Wang YG, Dai JL, Shang GD. Genetically engineered bacterial strain spiramycin streptomycete spiramyceticus WSJ-195 of bitespiramycin: CN, 02148771.5. 2004-10-06 (in Chinese). Liu J, Zhang Y, He W. Construction of a novel carrimycin-producing strain by using CRISPR-Cas9 and ribosome engineering techniques. Chin J Biotechnol. 2021; 37(6):2116–2126. Wang HY, Zhou HX, Dai JL, et al. Studies on space-flight breeding of genetically engineered strain of biotechmycin. Chin J Pharm Biotechnol. 2007;14(1):10–13 (in Chinese). Dai JL, Li RF, Wu LZ, et al. Improvement of new generation of bitespiramycin producing strain by microwave radiation. Chin J Antibiot. 2009;34(7): 406–410, 428 (in Chinese). Dai JL, Li RF, WANG YG, WU LZ, He WQ. Optimization of fermentation medium for bitespiramycin production by response surface methodology. Journal of Shenyang Pharmaceutical University. 2010;27(6):482–488 (in Chinese). Li Z, Wang Y, Chu J, Zhuang Y, Zhang S. Leucine improves the component of isovalerylspiramycins for the production of bitespiramycin. Bioprocess Biosyst Eng. 2009;32:641-647. Gao X, Wang Y, Chu J. A preliminary study on the impact of exogenous A-Factor analogue 1,4-butyrolactone on stimulating bitespiramycin biosynthesis. Bioprocess Biosyst Eng. 2019, 42(12):1903–1913. Dai JL, Wang YH, Liu YW, Xiao CY, Tong ZM, Chu J, Zhang SL, Lv GY, Wang YG. Study on the fermentation of genetically engineered strain of biotechmycin in fermentor. Chin J Antibiot. 2005;30(6):324–327, 428 (in Chinese). Lu Z, Zhang X, Dai J, Wang Y, He W. Engineering of leucine-responsive regulatory protein improves spiramycin and bitespiramycin biosynthesis. Microb Cell Fact. 2019;18(1):38. Dai JL, Zhang XT, Lu ZL, et al. Breeding of high isomycin-I-producing strain by MPMS composite mutagenesis with plasma and UV. Chin J Antibiot. 2018;43(2):182–188 (in Chinese). Xia H, Zhan X, Mao XM, Li YQ. The regulatory cascades of antibiotic production in Streptomyces. World J Microbiol Biotechnol. 2020;36(1):13. Li L, Wei K, Liu X, Wu Y, Zheng G, Chen S, Jiang W, Lu Y. aMSGE: advanced multiplex site-specific genome engineering withorthogonal modular recombinases in Actinomycetes. Metab Eng. 2019;52:153–167. Yu Z, Lv H, Wu Y, Wei T, Yang S, Ju D, Chen S. Enhancement of FK520 production in Streptomyces hygroscopicus by combining traditional mutagenesis with metabolic engineering. Appl Microbiol Biotechnol. 2019;103 (23–24):9593–9606. Xia M, Huang D, Li S, Wen J, Jia X, Chen Y. Enhanced FK506 production in Streptomyces tsukubaensis by rational feeding strategies based on comparative metabolic profiling analysis. Biotechnol Bioeng. 2013;110(10):2717–2730. Wang J, Liu H, Huang D, Jin L, Wang C, Wen J. Comparative proteomic and metabolomic analysis of Streptomyces tsukubaensis reveals the metabolic mechanism of FK506 overproduction by feeding soybean oil. Appl Microbiol Biotechnol. 2017;101(6):2447–2465. JungWS, Yoo YJ, Park JW, Park SR, Han AR, Ban YH, Kim EJ, Kim E, Yoon YJ. A combined approach of classical mutagenesis and rational metabolic engineering improves rapamycin biosynthesis and provides insights into methylmalonyl-CoA precursor supply pathway in Streptomyces hygroscopicus ATCC 29253. Appl Microbiol Biotechnol. 2011;91(5):1389–1397. Karray F, Darbon E, Oestreicher N, Dominguez H, Tuphile K, Gagnat J, Blondelet-Rouault MH, Gerbaud C, Pernodet JL, Organization of the biosynthetic gene cluster for the macrolide antibiotic spiramycin in Streptomyces ambofaciens . Microbiology. 2007;153:4111–4122. Wang W, Li S, Li Z, Zhang J, Fan K, Tan G, Ai G, Lam SM, Shui G, Yang Z, Lu H, Jin P, Li Y, Chen X, Xia X, Liu X, Dannelly HK, Yang C, Yang Y, Zhang S, Alterovitz G, Xiang W, Zhang L. Harnessing the intracellular triacylglycerols for titer improvement of polyketides in Streptomyces. Nat Biotechnol. 2020;38(1):76–83. Alvarez HM, Steinbuchel A. Triacylglycerols in prokaryotic microorganisms. Appl Microbiol Biotechnol. 2002;60:367–376. Karray F, Darbon E, Nguyen HC, Gagnat J, Pernodet JL. Regulation of the biosynthesis of the macrolide antibiotic spiramycin in Streptomyces ambofaciens . J Bacteriol. 2010;192:5813–5821. Dai J, Wang Y, Liu J, He W. The regulatory genes involved in spiramycin and bitespiramycin biosynthesis. Microbiol Res. 2020;240:126532. Xiang SH, Li J, Hua Yin, Zheng JT, Yang X, Wang HB, Luo JL, Bai H, Yang KQ. Application of a double-reporter-guided mutant selection method to improve clavulanic acid production in Streptomyces clavuligerus . Metab Eng. 2009;11(4-5):310–318. Xia H, Li X, Li Z, Zhan X, Mao X, Li Y. The Application of Regulatory Cascades in Streptomyces: Yield Enhancement and Metabolite Mining. Front Microbiol. 2020;11:406. Cundliffe E. Control of tylosin biosynthesis in Streptomyces fradiae . J Microbiol Biotechnol. 2008;18(9):1485–1491. Xu J, Song Z, Xu X, Ma Z, Bechthold A, Yu X. ToyA, a positive pathway-specific regulator for toyocamycin biosynthesis in Streptomyces diastatochromogenes Appl Microbiol Biotechnol. 2019;103(17):7071–7084. Zhu Z, Li H, Yu P, Guo Y, Luo S, Chen Z, Mao X, Guan W, Li Y. SlnR is a positive pathway-specific regulator for salinomycin biosynthesis in Streptomyces albus . Appl Microbiol Biotechnol. 2017;101(4):1547–1557. Zhang Y, He H, Liu H, Wang H, Wang X, Xiang W. Characterization of a pathway-specific activator of milbemycin biosynthesis and improved milbemycin production by its overexpression in Streptomyces bingchenggensis . Microb Cell Fact. 2016;15(1):152. Dai JL, Zhang XT, Lu ZL, et al. Breeding of high isomycin-I-producing strain by MPMS composite mutagenesis with plasma and UV. Chin J Antibiot. 2018;43 (2):182–188 (in Chinese) Wang L, Tian X, Wang J, Yang H, Fan K, Xu G, Yang K, Tan H. Autoregulation of antibiotic biosynthesis by binding of the end product to an atypical response regulator. Proc Natl Acad Sci U S A. 2009;106(21):8617–8622. Li X, Yu T, He Q, McDowall KJ, Jiang B, Jiang Z, Wu L, Li G, Li Q, Wang S, Shi Y, Wang L, Hong B. Binding of a biosynthetic intermediate to AtrA modulates the production of lidamycin by Streptomyces globisporus . Mol Microbiol. 2015;96(6):1257–1271. Lei C, Wang J, Liu Y, Liu X, Zhao G, Wang J. A feedback regulatory model for RifQ-mediated repression of rifamycin export in Amycolatopsis mediterranei . Microb Cell Fact. 2018;17(1):14. Malla S, Niraula NP, Liou K, Sohng JK. Self-resistance mechanism in Streptomyces peucetius: overexpression of drrA , drrB and drrC for doxorubicin enhancement. Microbiol Res. 2010;165(4):259–267. Xia H, Zhan X, Mao XM, Li YQ. The regulatory cascades of antibiotic production in Streptomyces. World J Microbiol Biotechnol. 2020;36(1):13. Kieser T, Bibb MJ, Butter MJ, Chater KF, Hopwood DA (2000) Practical Streptomyces genetics: a laboratory manual. The John Innes Foundation, Norwich. Wang YG, Jin LF, Jin WZ, Zhang XH, Zeng Y, Xu XM, Jun Y. Cloning and expression of midecamycin 4”-acylase gene in spiramycin producing strain. Chin J Biotechnol. 1992;8:1–14. Additional Declarations No competing interests reported. Supplementary Files SupplementaryTable.docx Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-1204059","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":75344747,"identity":"2fbd7f33-b2ce-4370-b94e-8ece3ba94312","order_by":0,"name":"Kemeng Li","email":"","orcid":"","institution":"NHC Key Laboratory of Biotechnology of Antibiotics, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Kemeng","middleName":"","lastName":"Li","suffix":""},{"id":75344748,"identity":"1dec499c-2eca-4890-a553-c55eb43c60b2","order_by":1,"name":"Jianlu Dai","email":"","orcid":"","institution":"NHC Key Laboratory of Biotechnology of Antibiotics, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Jianlu","middleName":"","lastName":"Dai","suffix":""},{"id":75344749,"identity":"74e125ea-637d-441d-bb1d-d463f07cf31d","order_by":2,"name":"Juanjuan Liu","email":"","orcid":"","institution":"NHC Key Laboratory of Biotechnology of Antibiotics, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Juanjuan","middleName":"","lastName":"Liu","suffix":""},{"id":75344750,"identity":"a993da55-b4cb-4b7e-b9b3-68e3d6d29b2a","order_by":3,"name":"Tianyi Hao","email":"","orcid":"","institution":"NHC Key Laboratory of Biotechnology of Antibiotics, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Tianyi","middleName":"","lastName":"Hao","suffix":""},{"id":75344751,"identity":"1773291b-26d5-46c1-82a4-8863a9c9771a","order_by":4,"name":"Weiqing He","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAABAklEQVRIiWNgGAWjYBACAxCRwCDBwMDe2MAMF+YhSgvPQVK0gIFEAgNxWszZewwfPCizyJOPfNy6uYDhTuLa9gOMD962Mcib49Bi2XPG2CDhnESx4e3EttszGJ4lbjuTwGw4t43BcGcDDofdyN0mkdgmkbhxNlALD8PhxG03GNikedsYEgwO4NBy/+32H2AtMw/CtbD/xqvlBu82BpCW+RKMCFuY8Wo5k/9ZAuiXxA08IL8YPDPediaxWXLOOQnDDbi0HD+W+PFHWV3i/Pbjz24XVNyR3Xb88MEPb8ps5HHZAgFsQL1gBWCSsQFISOBTD9Ei3wBm4TV5FIyCUTAKRigAAFoTZTMKjs8PAAAAAElFTkSuQmCC","orcid":"","institution":"NHC Key Laboratory of Biotechnology of Antibiotics, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College","correspondingAuthor":true,"submittingAuthor":false,"prefix":"","firstName":"Weiqing","middleName":"","lastName":"He","suffix":""}],"badges":[],"createdAt":"2021-12-25 11:29:01","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-1204059/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-1204059/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":17331413,"identity":"55f18ce4-c1f3-4d92-ac27-48436060fa59","added_by":"auto","created_at":"2022-01-14 17:47:47","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":54428,"visible":true,"origin":"","legend":"\u003cp\u003eBioinformatics analysis of \u003cem\u003esspD\u003c/em\u003e gene and construction of target genes under control different promoters. A: Alignment of the \u003cem\u003esco6196\u003c/em\u003e and \u003cem\u003esspD\u003c/em\u003e gene clusters in \u003cem\u003eStreptomyces coelicolor\u003c/em\u003e A3(2) and \u003cem\u003eStreptomyces spiramyceticus \u003c/em\u003e54IA, respectively. B: Construction of target genes under control different promoters in \u003cem\u003eStreptomyces spiramyceticus \u003c/em\u003e54IA. The genes are indicated by various colors. The \u003cem\u003esco6196\u003c/em\u003e and \u003cem\u003esspD\u003c/em\u003e genes are in red color and the regulatory genes in green color. Promoters of interest (Ptarget) are indicated by black arrows.\u003c/p\u003e","description":"","filename":"FIG1.png","url":"https://assets-eu.researchsquare.com/files/rs-1204059/v1/301d2caae2e10035699c455b.png"},{"id":17331414,"identity":"0110e3cd-da50-4627-9575-340b33d06149","added_by":"auto","created_at":"2022-01-14 17:47:47","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":506302,"visible":true,"origin":"","legend":"\u003cp\u003eThe characterization of F1R and F2R mutants.\u003cstrong\u003e \u003c/strong\u003eA: The titer of F1R mutants from pDR-42 F1R double-reporter system screening. 54IA: original strain \u003cem\u003eS\u003c/em\u003e. \u003cem\u003espiramyceticus \u003c/em\u003e54IA containing the pDR2 plasmid, F1R: the original pDR-42 F1R plasmid transformant, 1-23: the positive F1R mutants. B: The titer of F2R mutants from pDR-42F1R double-reporter system screening. 54IA: original strain 54IA, F1R: the original pDR-42F2R plasmid transformant, 1-21: the positive F2R mutants. The carrimycin titer is indicated as fold changes obtained by dividing mean value of each strain by the value of \u003cem\u003eS\u003c/em\u003e. \u003cem\u003espiramyceticus \u003c/em\u003e54IA. Error bars indicate the average standard deviations from the mean. C: F1R (a) and F2R (b) mutant colonies on selection plate sprayed with catechol. Black arrow: the typical false positive mutant, showing elevated kanamycin resistance but no observable XylE activity; blue arrow: the typical \u003cem\u003exylE\u003c/em\u003e over-expressing mutant (yellow). (c) Comparison of F1R-4 (left, No. 4 mutant), F2R-15 (right, No.15 mutant) and 54IA strain containing the pDR2 plasmid (under).\u003c/p\u003e","description":"","filename":"FIG2.png","url":"https://assets-eu.researchsquare.com/files/rs-1204059/v1/8a1d8cddd2c522b39783f2e8.png"},{"id":17331412,"identity":"971e8794-ef4c-458d-9f5c-81cd4435e754","added_by":"auto","created_at":"2022-01-14 17:47:47","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":31465,"visible":true,"origin":"","legend":"\u003cp\u003eqPCR of some up-regulated genes in the F2R-15 mutant and 54IA starting strains (n=3).\u003c/p\u003e\u003cp\u003e\u003cbr\u003e\u003c/p\u003e","description":"","filename":"FIG3.png","url":"https://assets-eu.researchsquare.com/files/rs-1204059/v1/8ef83365a36f5b73bdb37142.png"},{"id":18397876,"identity":"6430db3b-bd44-425d-a8e9-b0da0959da85","added_by":"auto","created_at":"2022-02-19 12:29:19","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":1014256,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-1204059/v1/cfb5a724-bddf-4ca9-a317-59d93f9994fb.pdf"},{"id":17331411,"identity":"34f8e57f-fe9b-4533-9121-fa49bf5a518b","added_by":"auto","created_at":"2022-01-14 17:47:47","extension":"docx","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":17862,"visible":true,"origin":"","legend":"","description":"","filename":"SupplementaryTable.docx","url":"https://assets-eu.researchsquare.com/files/rs-1204059/v1/1e14d8d44f9c5ea85f1861f1.docx"}],"financialInterests":"No competing interests reported.","formattedTitle":"\u003cp\u003eEnhancement of Carrimycin Production Via Traditional Mutagenesis with Metabolic Engineering in \u003cem\u003eStreptomyces Spiramyceticus\u003c/em\u003e 54IA\u003c/p\u003e","fulltext":[{"header":"Background","content":"\u003cp\u003eCarrimycin, also known as bitespiramycin and shengjimycin, is a new, hybrid macrolide antibiotic approved by the China National Medical Products Administration in 2019. It is produced by recombinant \u003cem\u003eStreptomyces spiramyceticus\u003c/em\u003e, which harbors a 4\u0026Prime;-\u003cem\u003eO\u003c/em\u003e-isovaleryltransferase gene (\u003cem\u003eist\u003c/em\u003e) from \u003cem\u003eStreptomyces thermotolerans\u003c/em\u003e [1, 2]. Carrimycin mainly consisted of isovalerylspiramycins I, II, III and contained trace amount of other 4\u0026Prime;-\u003cem\u003eO\u003c/em\u003e-acylspiramycin components [3]. Compared to spiramycin, carrimycin has a longer half-life, higher potency, and greater tissue penetration [4, 5]; it shows potent inhibition to the G\u003csup\u003e+\u003c/sup\u003e pathogens, and recently was identified as an antiviral agent against a broad-spectrum of human coronaviruses, including the SARS-Cov-2 virus [6].\u003c/p\u003e\n\u003cp\u003eThe carrimycin engineering strain, \u003cem\u003eStreptomyces spiramyceticus\u003c/em\u003e WSJ-195 [7], was resistant to apramycin, thiostreptomycin and kanamycin, and it is difficult to perform directed genetic manipulation for this strain using the existing Streptomyces plasmids. So, a novel carrimycin-producing strain (\u003cem\u003eStreptomyces spiramyceticus\u003c/em\u003e 54IA) without resistant genes insertion into the genome was constructed by using CRISPR-Cas9 editing system [8]. The titer of carrimycin was improved through the ribosome engineering, but it was far from the requirement in the scale-up fermentation. Many efforts have been made to improve the production of carrimycin in \u003cem\u003eStreptomyces spiramyceticus\u003c/em\u003e WSJ\u0026minus;195 in recent years, including traditional random mutagenesis [9, 10], medium optimization [11], exogenous feeding strategies [12, 13], fermentation process control [14], and genetic engineering [15]. Among these approaches, traditional mutagenesis is a powerful and easily operated method for strain improvement in \u003cem\u003eStreptomyces\u003c/em\u003e, especially for microbes with less understanding of genomic information and metabolic mechanisms. Although the isovalerylspiramycins I (one component of carrimycin) high-producing strains have been developed with the composite mutagenesis of Plasma and UV [16], it is definitely laborious and time-consuming to improve carrimycin production by just relying on random mutagenesis and ordinary screen methods. Thus, traditional mutagenesis should combine with rational metabolic engineering strategies to shorten the process of strain breeding.\u003c/p\u003e\n\u003cp\u003eMetabolic engineering strategies have been widely used in the improvement of secondary metabolites in microbes, especially for the production of antibiotics. Currently, the improved production of antibiotics through metabolic engineering mainly focuses on investigation of regulatory genes [17], improvement of precursor supply [18, 19], and comparative metabolomics profiling analysis [20, 21]. Among those strategies, enhanced precursor supply has been indicated to be a direct way to increase the accumulation of desired natural products. For example, the increased supply of propionyl-CoA carboxylase along with the addition of propionate was found to be an effective way to increase the concentration of intracellular methylmalonyl-CoA for rapamycin biosynthesis in \u003cem\u003eS. hygroscopicus\u003c/em\u003e [22]. Spiramycin\u0026rsquo;s structural backbone is a polyketide, putative platenolide I including ethylmalonyl-CoA, methylmalonyl-CoA and methoxymalonyl-CoA, which depends on polyketides synthase (PKS) and malonyl-CoA for its biochemical composition [23]. Wang et al [24] applied multi-omics to reveal that intracellular triacylglycerols (TAGs) pool as an intracellular carbon source for polyketide biosynthesis during stationary phase, and the mobilization of cellular TAGs enables carbon flux to be redirected to polyketide biosynthesis. They devised a new dynamic degradation of TAG (ddTAG) strategy that increases polyketide titers and applied ddTAG in four Streptomyces species to increase yields of actinorhodin (Act), jadomycin B, oxytetracycline and avermectin B1a. The \u003cem\u003esco6196\u003c/em\u003e is the key gene involved in degradation of TAG in \u003cem\u003eS. coelicolor\u003c/em\u003e. Given that accumulation of a TAG pool is widespread in actinomycetes [25]. The strategy of TAG appropriately degradation can be also widely used for improvement of polyketide antibiotics biosynthesis.\u003c/p\u003e\n\u003cp\u003eThe positive regulatory genes of spiramycin biosynthesis, \u003cem\u003esrm22\u003c/em\u003e and \u003cem\u003esrm40\u003c/em\u003e, also were identified in this gene cluster. Srm40 is a pathway-specific activator in spiramycin biosynthesis, and Srm22 is required for \u003cem\u003esrm40\u003c/em\u003e expression [26]. The \u003cem\u003ebsm23\u003c/em\u003e and \u003cem\u003ebsm42\u003c/em\u003e genes in \u003cem\u003eStreptomyces spiramyceticus\u003c/em\u003e, homologous with \u003cem\u003esrm22\u003c/em\u003e and \u003cem\u003esrm40\u003c/em\u003e, also play the positive regulatory genes involved in spiramycin biosynthesis [27]. The Bsm42 plays the role in the activation of spiramycin biosynthesis, and its overexpression can improve the yield of spiramycin. However, we discovered that Bsm23 inhibited spiramycin production at high expression level although it was a necessary regulatory gene for spiramycin biosynthesis. The expression level of the transcriptional activators can play as an indicator for high production of target metabolite. A double reporter-guided mutant selection method has been developed to facilitate selection of clavulanic acid high-yield mutants [28].\u003c/p\u003e\n\u003cp\u003eCarrimycin is a new potent drug for anti-infection and had antiviral activity. We constructed a new resistant marker-free strain \u003cem\u003eStreptomyces spiramyceticus\u003c/em\u003e 54IA by CRISPR-Cas9 editing system. But the carrimycin production of 54IA is far lower than that of the WSJ-195 strain. In this study, the carrimycin production was improved by increasing expression of \u003cem\u003esspD\u003c/em\u003e, homologous to \u003cem\u003esco6196\u003c/em\u003e, through introducing extra \u003cem\u003esspD \u003c/em\u003ecopy under the control of the promoter of carrimycin biosynthetic genes. The more concentration of SspD at appropriate time means the more the precursors degraded from of TAG for carrimycin biosynthesis. Furthermore, investigation and manipulation of the positive regulator is another effective way to enhance the yield of carrimycin.\u003c/p\u003e"},{"header":"Results","content":"\u003cp\u003e\u003cstrong\u003eThe analysis of \u003c/strong\u003e\u003cstrong\u003eSspD, homolog of \u003c/strong\u003e\u003cstrong\u003eSCO6196\u003c/strong\u003e,\u003cstrong\u003e in \u003cem\u003estreptomyces spiramyceticus\u003c/em\u003e 54IA\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSCO6196 is AMP-binding domain-containing protein to activate fatty acids by binding to coenzyme A in the \u003cem\u003eStreptomyces coelicolor\u003c/em\u003e A3 (2). It can channel carbon flux from both intracellular TAGs and extracellular substrates into polyketide biosynthesis. SspD in \u003cem\u003eStreptomyces spiramyceticus\u003c/em\u003e 54IA (533 amino acid residues) had high sequence similarity (80% identity and 88% similarity) to the SCO6196 from \u003cem\u003eStreptomyces coelicolor\u003c/em\u003e A3 (2). However, its upstream and downstream genes display significantly difference with that of \u003cem\u003esco6196 \u003c/em\u003e(Figure 1A).\u003c/p\u003e\n\u003cp\u003eIn order to gain the improvement of expressing \u003cem\u003esspD\u003c/em\u003e to supply more precursors for carrimycin biosynthesis, the extra constructed \u003cem\u003esspD\u003c/em\u003e gene was driven by the P\u003cem\u003epks\u003c/em\u003e or P\u003cem\u003ebsm42\u003c/em\u003e promoter in the carrimycin biosynthetic gene cluster, both of which were activated during the stationary phase of the host strain. Plasmids pSET-\u003cem\u003ePpks-sspD\u003c/em\u003e and pSET-\u003cem\u003ePbsm42-sspD\u003c/em\u003e were thus constructed (Figure 1B) and used to transform 54IA strain to obtain strain 54IA::\u003cem\u003ePpks-\u003c/em\u003e\u003cem\u003esspD\u003c/em\u003e and 54IA::\u003cem\u003ePbsm42-\u003c/em\u003e\u003cem\u003esspD\u003c/em\u003e.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable 1 \u003c/strong\u003eFermentation titer of the wild-type strain and transformants\u003c/p\u003e\n\u003ctable border=\"1\" width=\"0\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd width=\"148\"\u003e\n\u003cp\u003eStrains\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"113\"\u003e\n\u003cp\u003eFermentation titer（\u0026mu;g/mL）\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"248\"\u003e\n\u003cp\u003eConcentration of isovalerylspiramycins\u003c/p\u003e\n\u003cp\u003e（\u0026mu;g/mL）\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"148\"\u003e\n\u003cp\u003e54IA\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"113\"\u003e\n\u003cp\u003e115\u0026plusmn;13.96\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"248\"\u003e\n\u003cp\u003e56.17\u0026plusmn;4.31\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"148\"\u003e\n\u003cp\u003e54IA::\u003cem\u003ePpks-sspD\u003c/em\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"113\"\u003e\n\u003cp\u003e253\u0026plusmn;12.75\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"248\"\u003e\n\u003cp\u003e93.63\u0026plusmn;6.63\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"148\"\u003e\n\u003cp\u003e54IA::\u003cem\u003ePbsm42-sspD\u003c/em\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"113\"\u003e\n\u003cp\u003e187\u0026plusmn;9.42\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"248\"\u003e\n\u003cp\u003e79.74\u0026plusmn;3.96\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"148\"\u003e\n\u003cp\u003e54IA::\u003cem\u003ekasOp*\u003c/em\u003e-\u003cem\u003ebsm42\u003c/em\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"113\"\u003e\n\u003cp\u003e964\u0026plusmn;34.87\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"248\"\u003e\n\u003cp\u003e325.04\u0026plusmn;19.45\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"148\"\u003e\n\u003cp\u003e54IA::\u003cem\u003ekasOp*\u003c/em\u003e-\u003cem\u003ebsm23\u003c/em\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"113\"\u003e\n\u003cp\u003e276\u0026plusmn;18.55\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"248\"\u003e\n\u003cp\u003e65.75\u0026plusmn;8.21\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eDate are means \u0026plusmn; SE of three independent biological replicates\u003c/p\u003e\n\u003cp\u003e54IA::\u003cem\u003ePpks-\u003c/em\u003e\u003cem\u003esspD\u003c/em\u003e and 54IA::\u003cem\u003ePbsm42-\u003c/em\u003e\u003cem\u003esspD\u003c/em\u003e showed higher titer than that of the original strain 54IA. As shown in Table 1, the titer of 54IA::\u003cem\u003ePpks-\u003c/em\u003e\u003cem\u003esspD\u003c/em\u003e and 54IA::\u003cem\u003ePbsm42-\u003c/em\u003e\u003cem\u003esspD\u003c/em\u003e reached 253\u0026plusmn;12.75 \u0026mu;g/mL and 187\u0026plusmn;9.42 \u0026mu;g/mL, which are 2.2 and 1.6 times higher than that of 54IA, respectively. In order to calculate the yield of the isovalerylspiramycins, the three main active components of carrimycin, the fermentation broth extractions of the strains were analyzed by HPLC. Based on the standard curves of carrimycin, the isovalerylspiramycins yield of in strain 54IA\u003cem\u003e::Ppks-sspD \u003c/em\u003e(93.63\u0026plusmn;6.63 \u0026mu;g/mL) and 54IA::\u003cem\u003ePbsm42-\u003c/em\u003e\u003cem\u003esspD \u003c/em\u003e(79.74 \u0026mu;g/mL) (Table 1) were significantly increased than that of 54IA (56.17\u0026plusmn;4.31 \u0026mu;g/mL). The results suggest that improved \u003cem\u003esspD\u003c/em\u003e expression at suitable time controlled by the appropriate promoter could effectively enhance the yield of carrimycin in 54IA strain.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEnhancement of \u003c/strong\u003e\u003cstrong\u003ecarrimycin\u003c/strong\u003e\u003cstrong\u003e production \u003c/strong\u003e\u003cstrong\u003eby overexpression of \u003c/strong\u003e\u003cstrong\u003eBsm23 and Bsm42 \u003c/strong\u003e\u003cstrong\u003epositive \u003c/strong\u003e\u003cstrong\u003etranscription regulators\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eIt has been reported that Bsm23 and Bsm42 are two positive regulators of the spiramycin biosynthesis. To investigate the performance of Bsm23 and Bsm42 in the regulation of carrimycin biosynthesis, \u003cem\u003ebsm23\u003c/em\u003e and \u003cem\u003ebsm4\u003c/em\u003e\u003cem\u003e2\u003c/em\u003ewere both overexpressed in 54IA strain. Plasmid pSET-\u003cem\u003ekasOp*-bsm23\u003c/em\u003e containing \u003cem\u003ebsm23 \u003c/em\u003eassembled with \u003cem\u003ekasOp* \u003c/em\u003epromoter was constructed, and plasmid pSET-\u003cem\u003ekasOp*-bsm42\u003c/em\u003e contained \u003cem\u003ebsm42 \u003c/em\u003ewhich was also driven by \u003cem\u003ekasOp* \u003c/em\u003epromoter (Figure 1B). The two recombinant plasmids were then transferred into 54IA to give strain 54IA::\u003cem\u003e kasOp*-bsm23\u003c/em\u003e and 54IA:: \u003cem\u003ekasOp*-bsm42\u003c/em\u003e.\u003c/p\u003e\n\u003cp\u003eIn Table 1, the results showed that the titer of strain 54IA::\u003cem\u003ekasOp*-bsm42\u003c/em\u003e reached as high as 964\u0026plusmn;34.87 \u0026mu;g/mL, which was 7.4 times higher than that of the original strain 54IA. Meanwhile, its isovalerylspiramycins yield could improve to 325.04\u0026plusmn;19.45 \u0026mu;g/mL, about 5.8 fold higher than that of 54IA. In contrast, the fermentation titer of strain 54IA::\u003cem\u003ekasOp*-bsm23\u003c/em\u003e was moderately improved 2.4 times than that of 54IA, but the isovalerylspiramycins production was similar with that of 54IA. Therefore, Bsm42 was the pathway-specific positive activator for carrimycin biosynthesis. So, the improved expression level of \u003cem\u003ebsm42\u003c/em\u003e could play as an indicator for high production of carrimycin in 54IA strain.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eDouble reporter plasmid\u003c/strong\u003e\u003cstrong\u003es\u003c/strong\u003e\u003cstrong\u003e for \u003c/strong\u003e\u003cstrong\u003eefficient\u003c/strong\u003e\u003cstrong\u003e screening for \u003c/strong\u003e\u003cstrong\u003ecarrimycin \u003c/strong\u003e\u003cstrong\u003ehigh-yield strain\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSimilar to other pathway-specific positive activator, the promoter region of \u003cem\u003ebsm42\u003c/em\u003e could play a direct target for variety of regulatory proteins. We attempt to adjust the expression of \u003cem\u003ebsm42\u003c/em\u003e through mutagenesis method combining with a reporter system to serve as a screening indicator. By protoplast transformation methods, the reporter plasmids pDR-42F1R and pDR-42F2R were transduced into 54IA to obtain the F1R and F2R transformants, respectively. It was found that the wild type strain 54IA could normally grow below 2 \u0026mu;g/mL of kanamycin (Km), however the F1R and F2R could maximally tolerate Km at 60 \u0026mu;g/mL. About 1\u0026times;10\u003csup\u003e5\u003c/sup\u003e spores of F1R and F2R were separately treated with UV and plasma, followed by spreading spores on greater than or equal to 60 \u0026mu;g/mL of Km. The hundreds of mutants grew out for 7 days of incubation, and then the selection plates were sprayed with catechol. 608 yellow-colored mutants were randomly picked for carrimycin titer measurement. The 286 mutants (47%) produced statistically higher carrimycin yield than the starting strain 54IA containing the pDR2 plasmid (Figure 2 and Table 2). The titers of positive F1R transformants (Figure 2A) were much lower than that of the selected F2R tranformants. Among F2R tranformants tested in Figure 2B, F2R-15 strain with the 200 \u0026mu;g/mL of Km resistance had the highest titer, reaching at a concentration of 1010\u0026plusmn;30 \u0026mu;g/mL.\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable 2 \u003c/strong\u003ePositive rates of different F1R and F2R mutant pools\u003cstrong\u003e\u0026nbsp; \u003c/strong\u003e\u003c/p\u003e\n\u003ctable border=\"1\" width=\"0\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd width=\"154\"\u003e\n\u003cp\u003eMutant (Km \u0026mu;g/mL)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"217\"\u003e\n\u003cp\u003eThe number of positive strain/total\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"123\"\u003e\n\u003cp\u003ePositive rate\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"154\"\u003e\n\u003cp\u003eF1R (60)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"217\"\u003e\n\u003cp\u003e71/147\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"123\"\u003e\n\u003cp\u003e48%\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"154\"\u003e\n\u003cp\u003eF2R (90)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"217\"\u003e\n\u003cp\u003e99/111\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"123\"\u003e\n\u003cp\u003e89%\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"154\"\u003e\n\u003cp\u003eF2R (150)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"217\"\u003e\n\u003cp\u003e87/174\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"123\"\u003e\n\u003cp\u003e50%\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"154\"\u003e\n\u003cp\u003eF2R (200)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"217\"\u003e\n\u003cp\u003e18/89\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"123\"\u003e\n\u003cp\u003e20%\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"154\"\u003e\n\u003cp\u003eF2R (300)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"217\"\u003e\n\u003cp\u003e11/87\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"123\"\u003e\n\u003cp\u003e13%\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"154\"\u003e\n\u003cp\u003eTotal\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"217\"\u003e\n\u003cp\u003e286/608\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"123\"\u003e\n\u003cp\u003e47%\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eAs shown in Figure 2C, only a few of F1R mutant colonies (Figure. 2C-a) was visually observable yellow color appeared on the lawns, but most of F2R mutant colonies (Figure 2C-b) displayed the significant yellow color. The XylE activities were tested in the highest yield mutants of F1R-4 and F2R-15 (Fig. 2C-c). When sprayed with substrate catechol, the colonies of F2R-15 displayed bright yellow color, at the same time the colonies of F1R-4 showed weak yellow color, while there was no visible yellow color appeared on the lawns of the starting strain 54I-A.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eDifferentially expressed genes between the high-yield strain F2R-15 and 54IA\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eComparative analysis of transcriptome profiles from RNA-seq of the F2R-15 mutant and 54IA strains found 44 genes with obvious differences in expression, including 20 significantly up-regulated and 24 down-regulated genes (Table 3). The up-regulated genes are associated with carrimycin biosynthetic precursor, macrolide-inactivation, antibiotics transporter, oxidative phosphorylation, two sigma factors and three regulators. The improved genes of ID-6064 and ID-203 are related to the generation of acyl-CoA and Isovaleryl-CoA, which are the important building blocks of carrimycin biosynthesis. Gene of ID-803, macrolide-inactivating glycosyltransferase gene, could play an important role in self-protection to macrolide antibiotic inhibition. There are 7 enhanced expression genes involved in transporter system, especially the response to antibiotic. In addition, some increased genes referring to oxidative phosphorylation might provide more energy for the secondary metabolism. The improvement of sigma factors and three regulatory genes may be directly or indirectly involved in regulating the biosynthesis of carrimycin. The most of down-regulated genes were attributed to 10 secondary metabolites gene clusters referring to the biosynthesis of siderphore, terpene, lassopeptide, feglymycin, ectoine and some \u003cem\u003et1pks\u003c/em\u003e-\u003cem\u003enrps\u003c/em\u003e compounds. Strangely, the deoxysugar biosynthetic genes of carrimycin in F2R-15 mutant also showed lower expression level than that in 54IA. As for genes in synthesis and metabolism of bio-macromolecules, some important genes involved in metabolism of amino acids and nucleotides were increased, however, the key biosynthetic genes of the two primary metabolites were decreased. These results are consistent with the general knowledge that the secondary metabolism initiation would inhibit the primary metabolism.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable 3 \u003c/strong\u003eDifferentially expressed genes between the F2R-15 mutant and 54IA\u003c/p\u003e\n\u003ctable border=\"1\" width=\"0\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd width=\"73\"\u003e\n\u003cp\u003eID\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"378\"\u003e\n\u003cp\u003eGene description\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"85\"\u003e\n\u003cp\u003eRegulation\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003eFold change\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"283\"\u003e\n\u003cp\u003ePathway description\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"5\" width=\"877\"\u003e\n\u003cp\u003ePrecursor biosynthesis\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"73\"\u003e\n\u003cp\u003e6064\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"378\"\u003e\n\u003cp\u003epyruvate dehydrogenase E1 component subunit alpha\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"85\"\u003e\n\u003cp\u003eUP\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e6.34\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"283\"\u003e\n\u003cp\u003eGlycolysis, acyl-CoA biosynthesis\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"73\"\u003e\n\u003cp\u003e203\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"378\"\u003e\n\u003cp\u003eDNA alkylation response protein,\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"85\"\u003e\n\u003cp\u003eUP\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e2.22\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"283\"\u003e\n\u003cp\u003eIsovaleryl-CoA dehydrogenase activity, the leucine degradation pathway\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"5\" width=\"877\"\u003e\n\u003cp\u003eMacrolide-inactivating\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"73\"\u003e\n\u003cp\u003e803\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"378\"\u003e\n\u003cp\u003emacrolide-inactivating glycosyltransferase\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"85\"\u003e\n\u003cp\u003eUP\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e3.68\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"283\"\u003e\n\u003cp\u003eResponse to macrolide antibiotic\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"5\" width=\"877\"\u003e\n\u003cp\u003eTransporter\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"73\"\u003e\n\u003cp\u003e2176\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"378\"\u003e\n\u003cp\u003eABC transporter permease\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"85\"\u003e\n\u003cp\u003eUP\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e5.17\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"283\"\u003e\n\u003cp\u003eEfflux transmembrane transporter activity\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"73\"\u003e\n\u003cp\u003e5715\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"378\"\u003e\n\u003cp\u003eEsterase\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"85\"\u003e\n\u003cp\u003eUP\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e4.49\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"283\"\u003e\n\u003cp\u003eATPase activity, glycine betaine transport\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"73\"\u003e\n\u003cp\u003e711\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"378\"\u003e\n\u003cp\u003eATP-binding protein DrrA\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"85\"\u003e\n\u003cp\u003eUP\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e4.43\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"283\"\u003e\n\u003cp\u003eDaunorubicin \u0026nbsp;resistance ABC transporter\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"73\"\u003e\n\u003cp\u003e696\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"378\"\u003e\n\u003cp\u003eABC-F family protein\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"85\"\u003e\n\u003cp\u003eUP\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e3.76\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"283\"\u003e\n\u003cp\u003eATPase activity, response to antibiotic\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"73\"\u003e\n\u003cp\u003e518\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"378\"\u003e\n\u003cp\u003eMFS transporter\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"85\"\u003e\n\u003cp\u003eUP\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e2.91\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"283\"\u003e\n\u003cp\u003eSporulation\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"73\"\u003e\n\u003cp\u003e1243\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"378\"\u003e\n\u003cp\u003eEfflux RND transporter permease subunit\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"85\"\u003e\n\u003cp\u003eUP\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e2.58\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"283\"\u003e\n\u003cp\u003eTransmembrane transporter activity, response to antibiotic\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"73\"\u003e\n\u003cp\u003e6822\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"378\"\u003e\n\u003cp\u003eABC transporter, \u003cem\u003esrmB\u003c/em\u003e(\u003cem\u003ebsm25\u003c/em\u003e)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"85\"\u003e\n\u003cp\u003eUP\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e2.00\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"283\"\u003e\n\u003cp\u003eATPase activity, response to antibiotic\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"5\" width=\"877\"\u003e\n\u003cp\u003eOxidative phosphorylation\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"73\"\u003e\n\u003cp\u003e5654\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"378\"\u003e\n\u003cp\u003eNADH-quinone oxidoreductase subunit L\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"85\"\u003e\n\u003cp\u003eUP\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e5.64\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd rowspan=\"4\" width=\"283\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eOxidative phosphorylation\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"73\"\u003e\n\u003cp\u003e2106\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"378\"\u003e\n\u003cp\u003eNADH-quinone oxidoreductase subunit M\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"85\"\u003e\n\u003cp\u003eUP\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e5.50\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"73\"\u003e\n\u003cp\u003e5817\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"378\"\u003e\n\u003cp\u003eNADH-quinone oxidoreductase subunit L\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"85\"\u003e\n\u003cp\u003eUP\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e4.38\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"73\"\u003e\n\u003cp\u003e84\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"378\"\u003e\n\u003cp\u003eNADH-quinone oxidoreductase subunit G\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"85\"\u003e\n\u003cp\u003eUP\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e2.80\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"5\" width=\"877\"\u003e\n\u003cp\u003eSigma factor\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"73\"\u003e\n\u003cp\u003e1068\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"378\"\u003e\n\u003cp\u003eSigE family RNA polymerase sigma factor\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"85\"\u003e\n\u003cp\u003eUP\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e2.79\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"283\"\u003e\n\u003cp\u003eDNA-binding transcription factor activity\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"73\"\u003e\n\u003cp\u003e699\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"378\"\u003e\n\u003cp\u003eSigma-70 family RNA polymerase sigma factor\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"85\"\u003e\n\u003cp\u003eUP\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e2.55\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"283\"\u003e\n\u003cp\u003eDNA-binding transcription factor activity\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"5\" width=\"877\"\u003e\n\u003cp\u003eRegulator\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"73\"\u003e\n\u003cp\u003e2796\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"378\"\u003e\n\u003cp\u003eVWA domain-containing protein\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"85\"\u003e\n\u003cp\u003eUP\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e6.11\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"283\"\u003e\n\u003cp\u003eATPase activity, signal transduction\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"73\"\u003e\n\u003cp\u003e1928\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"378\"\u003e\n\u003cp\u003eAfsR family transcriptional regulator\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"85\"\u003e\n\u003cp\u003eUP\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e4.56\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"283\"\u003e\n\u003cp\u003eRegulation of transcription (Hyphal growth)\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"73\"\u003e\n\u003cp\u003e709\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"378\"\u003e\n\u003cp\u003eHelix-turn-helix transcriptional regulato\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"85\"\u003e\n\u003cp\u003eUP\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e2.05\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"283\"\u003e\n\u003cp\u003ePhosphorelay signal transduction system\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"5\" width=\"877\"\u003e\n\u003cp\u003eAmino acid metabolism\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"73\"\u003e\n\u003cp\u003e1738\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"378\"\u003e\n\u003cp\u003e4-hydroxyphenylpyruvate dioxygenase\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"85\"\u003e\n\u003cp\u003eUP\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e5.13\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"283\"\u003e\n\u003cp\u003eTyrosine and phenylalanine metabolism\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"73\"\u003e\n\u003cp\u003e2137\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"378\"\u003e\n\u003cp\u003eglutamine synthetase\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"85\"\u003e\n\u003cp\u003eDOWN\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e5.81\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"283\"\u003e\n\u003cp\u003eGlutamine biosynthetic process\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"73\"\u003e\n\u003cp\u003e827\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"378\"\u003e\n\u003cp\u003eglutamate synthase large subunit\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"85\"\u003e\n\u003cp\u003eDOWN\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e3.48\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"283\"\u003e\n\u003cp\u003eGlutamate biosynthetic process\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"73\"\u003e\n\u003cp\u003e434\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"378\"\u003e\n\u003cp\u003e3-isopropylmalate dehydratase\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"85\"\u003e\n\u003cp\u003eDOWN\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e2.83\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"283\"\u003e\n\u003cp\u003eValine, leucine and isoleucine biosynthesis\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"5\" width=\"877\"\u003e\n\u003cp\u003eNucleotide metabolism\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"73\"\u003e\n\u003cp\u003e357\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"378\"\u003e\n\u003cp\u003epurine-nucleoside phosphorylase\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"85\"\u003e\n\u003cp\u003eDOWN\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e6.49\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"283\"\u003e\n\u003cp\u003ePurine metabolism, Pyrimidine metabolism\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"73\"\u003e\n\u003cp\u003e955\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"378\"\u003e\n\u003cp\u003eadenosine deaminase,\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"85\"\u003e\n\u003cp\u003eDOWN\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e5.00\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"283\"\u003e\n\u003cp\u003eNucleotide metabolic process\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"5\" width=\"877\"\u003e\n\u003cp\u003eSecondary metabolites gene clusters\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"73\"\u003e\n\u003cp\u003e1832\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"378\"\u003e\n\u003cp\u003eIucA/IucC family siderophore biosynthesis protein\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"85\"\u003e\n\u003cp\u003eDOWN\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e8.33\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd rowspan=\"3\" width=\"283\"\u003e\n\u003cp\u003eDesferrioxamine B biosynthetic gene cluster ( Siderophore)\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"73\"\u003e\n\u003cp\u003e1546\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"378\"\u003e\n\u003cp\u003eABC transporter substrate-binding protein\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"85\"\u003e\n\u003cp\u003eDOWN\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e7.69\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"73\"\u003e\n\u003cp\u003e2436\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"378\"\u003e\n\u003cp\u003easpartate aminotransferase family protein\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"85\"\u003e\n\u003cp\u003eDOWN\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e5.92\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"73\"\u003e\n\u003cp\u003e472\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"378\"\u003e\n\u003cp\u003eIucA/IucC family protein\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"85\"\u003e\n\u003cp\u003eDOWN\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e7.30\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"283\"\u003e\n\u003cp\u003eKanamycin biosynthetic gene cluster\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"73\"\u003e\n\u003cp\u003e730\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"378\"\u003e\n\u003cp\u003eiron chelate uptake ABC transporter family permease subunit\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"85\"\u003e\n\u003cp\u003eDOWN\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e4.55\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"283\"\u003e\n\u003cp\u003esiderophore \u0026nbsp;biosynthetic gene cluster\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"73\"\u003e\n\u003cp\u003e1398\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"378\"\u003e\n\u003cp\u003eserine hydroxymethyltransferase\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"85\"\u003e\n\u003cp\u003eDOWN\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e3.02\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd rowspan=\"2\" width=\"283\"\u003e\n\u003cp\u003eectoine-butyrolactone biosynthetic gene cluster\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"73\"\u003e\n\u003cp\u003e503\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"378\"\u003e\n\u003cp\u003eABC transporter permease subunit\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"85\"\u003e\n\u003cp\u003eDOWN\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e2.75\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"73\"\u003e\n\u003cp\u003e422\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"378\"\u003e\n\u003cp\u003epurine permease\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"85\"\u003e\n\u003cp\u003eDOWN\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e3.83\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd rowspan=\"2\" width=\"283\"\u003e\n\u003cp\u003et1pks-nrps metabolite biosynthetic gene cluster\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"73\"\u003e\n\u003cp\u003e1820\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"378\"\u003e\n\u003cp\u003eVWA domain-containing protein\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"85\"\u003e\n\u003cp\u003eDOWN\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e2.56\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"73\"\u003e\n\u003cp\u003e16\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"378\"\u003e\n\u003cp\u003eNDP-aminohexose N-dimethyltransferase (\u003cem\u003ebsm22\u003c/em\u003e)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"85\"\u003e\n\u003cp\u003eDOWN\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e3.27\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd rowspan=\"4\" width=\"283\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eDeoxysugar biosynthesis of spiramycin\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"73\"\u003e\n\u003cp\u003e92\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"378\"\u003e\n\u003cp\u003eNDP-hexose dehydratase (\u003cem\u003ebsm26\u003c/em\u003e)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"85\"\u003e\n\u003cp\u003eDOWN\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e2.76\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"73\"\u003e\n\u003cp\u003e74\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"378\"\u003e\n\u003cp\u003eGTPase (\u003cem\u003ebsm27\u003c/em\u003e)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"85\"\u003e\n\u003cp\u003eDOWN\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e2.39\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"73\"\u003e\n\u003cp\u003e18\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"378\"\u003e\n\u003cp\u003eglycosyltransferase, \u003cem\u003ebsm28\u003c/em\u003e-35\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"85\"\u003e\n\u003cp\u003eDOWN\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e2.26\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"73\"\u003e\n\u003cp\u003e530\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"378\"\u003e\n\u003cp\u003eDUF350 domain-containing protein\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"85\"\u003e\n\u003cp\u003eDOWN\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e3.22\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd rowspan=\"2\" width=\"283\"\u003e\n\u003cp\u003eTerpene \u0026nbsp;biosynthetic gene cluster\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"73\"\u003e\n\u003cp\u003e1046\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"378\"\u003e\n\u003cp\u003eiron-containing alcohol dehydrogenase family protein\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"85\"\u003e\n\u003cp\u003eDOWN\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e2.04\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"73\"\u003e\n\u003cp\u003e873\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"378\"\u003e\n\u003cp\u003ediaminobutyrate--2-oxoglutarate aminotransferase\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"85\"\u003e\n\u003cp\u003eDOWN\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e2.98\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"283\"\u003e\n\u003cp\u003eEctoine biosynthetic gene cluster\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"73\"\u003e\n\u003cp\u003e87\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"378\"\u003e\n\u003cp\u003epeptide-N4-asparagine amidase A\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"85\"\u003e\n\u003cp\u003eDOWN\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e2.83\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"283\"\u003e\n\u003cp\u003eFeglymycin biosynthetic gene cluster\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"73\"\u003e\n\u003cp\u003e857\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"378\"\u003e\n\u003cp\u003eAAA family ATPase\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"85\"\u003e\n\u003cp\u003eDOWN\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e2.24\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"283\"\u003e\n\u003cp\u003eladderane-nrps biosynthetic gene cluster\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"73\"\u003e\n\u003cp\u003e1704\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"378\"\u003e\n\u003cp\u003eacetylornithine transaminase\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"85\"\u003e\n\u003cp\u003eDOWN\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e2.10\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"283\"\u003e\n\u003cp\u003eLassopeptide \u0026nbsp;biosynthetic gene cluster\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eThe expressions of \u003cem\u003ebsm23 \u003c/em\u003e(ID-60), \u003cem\u003ebsm42\u003c/em\u003e (ID-834) and the major up-regulated genes were further validated repeatedly by qPCR (Figure 3). The results showed that the expression level of these up-regulated genes were essentially in agreement with that of trancriptome profiles, only gene 6064, 2176 and 2796 showed much higher expression level. However, the \u003cem\u003ebsm25 \u003c/em\u003e(ID-6822), \u003cem\u003ebsm42 \u003c/em\u003e(ID-834) and\u003cem\u003e bsm23\u003c/em\u003e (ID-60) located in carrimycin biosynthetic gene cluster had similar expression level between the F2R-15 mutant and 54IA starting strains.\u003c/p\u003e"},{"header":"Discussion","content":"\u003cp\u003eIn this article, we explored the feasibility of increasing \u003cem\u003esspD\u003c/em\u003e expression and overexpression of positive transcriptional regulators, \u003cem\u003ebsm23\u003c/em\u003e and \u003cem\u003ebsm42\u003c/em\u003e, for improvement of the carrimycin production in the 54IA strain. The production of carrimycin was moderately increased in the plasmids inserted strain containing the \u003cem\u003esspD\u003c/em\u003e gene under control of the \u003cem\u003epks\u003c/em\u003e or \u003cem\u003ebsm42\u003c/em\u003e promoters. The SspD, SCO6196 homolog, was considered to involve in degradation of TAG to produce the synthetic substrates for carrimycin biosynthesis in 54IA strain. The extra \u003cem\u003esspD\u003c/em\u003e gene copy was designed to expression at the starting period of carrimycin biosynthesis to increase substrate supply for PKS assemble line. This strategy just moderately improved carrimycin biosynthesis probably due to insufficient Ssp improved expression on the control of the \u003cem\u003epks\u003c/em\u003e or \u003cem\u003ebsm42\u003c/em\u003e promoter in 54IA strain.\u003c/p\u003e\n\u003cp\u003eGenerally, the antibiotic production is stringently and elaborately regulated by pyramidal transcriptional regulatory cascades, including signaling pathways, global regulators, pathway-specific regulator, and feedback regulation [29]. Combination of different strategies to manipulate regulatory genes can achieve higher antibiotic production in both the native and/or heterologous host. There are many reports proved that overexpression of pathway specific positive regulators can improve the production of antibiotics, such as TylS or (especially) TylR for Tylosin [30], ToyA for toyocamycin biosynthesis [31], SlnR modulated salinomycin biosynthesis [32], and so on. In this study, the Bsm42 plays the similar role in carrimycin biosynthesis, and its overexpression can significantly enhance the yield of carrimycin. Bsm23, however, is also a necessary regulator for carrimycin biosynthesis, but its higher expression cannot significantly enhance the antibiotics yield. The expression level of positive regulator is not always related to the production of antibiotic. These positive regulators also emerged in other antibiotics producing strain. For example, overexpression of \u003cem\u003emilR \u003c/em\u003ewith a strong constitutive promoter led to decreasing of milbemycin production in \u003cem\u003eS. bingchenggensis\u003c/em\u003e [33]. In conclusion, the threshold of the over-expressed regulator was a key point to determine the production of antibiotic.\u003c/p\u003e\n\u003cp\u003eIn view of the production of carrimycin correlated with the level of the \u003cem\u003ebsm42\u003c/em\u003e expression, the two different length of promoter of \u003cem\u003ebsm42\u003c/em\u003e was ligated to two reporter genes acting as indicator for screening carrimycin enhanced mutants. In our previous work, a stable isovalerylspiramycin I high-producing strain yielding 2000 \u0026mu;g/mL was obtained though atmospheric and room temperature plasma mutagenesis combined ultraviolet radiation [34]. In this study, this mutagenesis method was used to treat the 54IA containing the reporter plasmids. The \u003cem\u003ebsm42\u003c/em\u003e promoter combined with two reporter genes is efficient selective marker for screening high production of carrimycin through Km resistant and color changes in mutants. The results demonstrated that the shorter promoter of the \u003cem\u003ebsm42\u003c/em\u003e was more suitable for selection of the carrimycin high-yield strains. The efficiently selected strain F2R-15 produced carrimycin at a concentration of 1010\u0026plusmn;30 \u0026mu;g/mL, which was about 9 times higher than that of the original strain 54IA. The F2R-15 was selected from the plate of Km at 200 \u0026mu;g/mL, but not from the higher resistant concentration of Km. These results suggested the continuous high expression of \u003cem\u003ebsm42\u003c/em\u003e was not always benefit for carrimycin biosynthesis.\u003c/p\u003e\n\u003cp\u003eThe up-regulated genes in transciptome profiles of F2R-15 strain and 54IA were related to the macrolide resistant, transport, biosynthetic precursors from TCA or amino acid catabolism. The feedback regulation is often brought by antibiotic to coordinate antibiotic production and transport. Evidences have shown that antibiotic, as ligand for proper regulator, affects the final production in \u003cem\u003eStreptomyces\u003c/em\u003e. The expression of antibiotic biosynthetic genes was modulated by the RedZ and undecylprodigiosin complex [35]. The activity of AtrA, which regulates primary and secondary metabolism, is reduced by lidamycin of\u003cem\u003e Streptomyces globisporus\u003c/em\u003e and actinorhodin (ACT) of \u003cem\u003eS. coelicolor\u003c/em\u003e [36]. Export of antibiotic is important for the producer to reduce the intracellular antibiotic concentration, which can relieve self-toxicity. In \u003cem\u003eAmycolatopsis mediterranei\u003c/em\u003e, \u003cem\u003e\u0026Delta;\u003c/em\u003e\u003cem\u003erifQ\u003c/em\u003e mutant brought overexpression of RifP. The accelerated export of rifamycin may reduce the intracellular rifamycin concentration, relieve other possible feedback inhibition of rifamycin biosynthesis and finally lead to more than two-fold improvement of rifamycin B production [37]. Overexpression of DrrC, which provide self-resistance to DNR and DXR, achieved 5.1-fold increase in DXR production in \u003cem\u003eS. peucetius\u003c/em\u003e ATCC 27952 [38]. Transporters enhance the efflux of the self-produced antibiotics, which can be an important strategy for self-protection from self-toxicity.\u003c/p\u003e\n\u003cp\u003eThe down-regulated genes were mainly located in the other secondary metabolites biosynthetic gene clusters, which might reduce competition for biosynthetic substrates and energy of carrimycin. The decreased genes involved in 10 secondary metabolites gene clusters for the biosynthesis of siderphore, terpene, lassopeptide, feglymycin, ectoine and some t1pks-nrps compounds. However, the most of carrimycin biosynthetic genes in F2R-15 were a little higher expression level than 54IA starting strain, and even the deoxysugar biosynthetic genes were decreased expression. The possible reason is the inappropriate harvesting time of the strains in which production of the carrimycin starts to decline.\u003c/p\u003e\n\u003cp\u003eThe above data showed that manipulation of regulatory cascades can be an efficient way to enhance the production of antibiotic. It is obvious that the balance and synergy between primary and secondary metabolism is very important for the overproduction of antibiotic. Rewiring regulatory network combined with metabolic engineering will be a more powerful way to enhance the production of antibiotic in \u003cem\u003eStreptomyces\u003c/em\u003e [39]. On the basis of understanding the regulation of antibiotic biosynthesis, rewiring the regulatory network is much more efficient to optimize antibiotic producers than the classical random mutagenesis methods.\u003c/p\u003e"},{"header":"Material and methods","content":"\u003cp\u003e\u003cstrong\u003eStrains, plasmids, culture conditions \u003c/strong\u003e\u003cstrong\u003eand \u003c/strong\u003e\u003cstrong\u003eprimers\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAll strains and plasmids used in this study are listed in Table S1. The original strain \u003cem\u003eStreptomyces spiramyceticus\u003c/em\u003e 54IA was generated from \u003cem\u003eS\u003c/em\u003e\u003cem\u003e.\u003c/em\u003e\u003cem\u003e spiramyceticus\u003c/em\u003e 1941 by inserting \u003cem\u003eist\u003c/em\u003e and \u003cem\u003eacyB2\u003c/em\u003e genes into the downstream of the spiramycin gene cluster [8]. The slant/plate medium, seed medium, and culture conditions for \u003cem\u003eS\u003c/em\u003e\u003cem\u003e.\u003c/em\u003e\u003cem\u003e spiramyceticus\u003c/em\u003e were prepared according to previously described methods [39]. \u003cem\u003eStreptomyces \u003c/em\u003estrains were cultivated at 28\u0026deg;C for 120 h in soluble fermentation medium for isolation of total RNA. Soluble fermentation medium (per 100 mL) contained: dextrin, 5.0 g; NaCl, 1g; MgSO\u003csub\u003e4\u003c/sub\u003e, 0.55 g; CaCO\u003csub\u003e3\u003c/sub\u003e, 0.5g; NH\u003csub\u003e4\u003c/sub\u003eNO\u003csub\u003e3\u003c/sub\u003e, 0.7g, KH\u003csub\u003e2\u003c/sub\u003ePO\u003csub\u003e4\u003c/sub\u003e, 0.065 g; ZnSO\u003csub\u003e4\u003c/sub\u003e\u0026bull;7H\u003csub\u003e2\u003c/sub\u003eO \u0026nbsp;0.01g; CoCl\u003csub\u003e2\u003c/sub\u003e, 5\u0026acute;10\u003csup\u003e-5\u003c/sup\u003e g; with pH adjusted to 7.2 before autoclaving. The primers used are listed in Table S2.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eDNA isolation, manipulation, sequencing, and bioinformatics analysis\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eRoutine DNA manipulation with \u003cem\u003eE. coli\u003c/em\u003e and recombinant DNA techniques in \u003cem\u003eStreptomyces\u003c/em\u003e species were performed as described previously [40]. Routine DNA sequencing was carried out by The Beijing Ruibiotech (Beijing, China). Primers were synthesized by Sangong (Shanghai, China). Protein secondary structure predictions were performed using the NCBI BLAST program (https://blast.ncbi.nlm.nih.gov/Blast.cgi). The multiple sequence alignments and homology comparisons were performed using Clustal W and BLAST software.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eGenetic manipulation\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAll plasmids constructed in this study were introduced into \u003cem\u003eS. spiramyceticus\u003c/em\u003e 54IA according to the PEG-assisted protoplast transformation method reported previously [41]. To investigate the availability of \u003cem\u003esco6196\u003c/em\u003e for improving carrimycin biosynthesis in \u003cem\u003eS. spiramyceticus\u003c/em\u003e 54IA, the plasmids, pSET-\u003cem\u003ePpks\u003c/em\u003e-\u003cem\u003esspD\u003c/em\u003e and pSET-\u003cem\u003ePbsm42\u003c/em\u003e-\u003cem\u003esspD\u003c/em\u003e, were constructed to increase the expression of \u003cem\u003esspD\u003c/em\u003e under the control of \u003cem\u003ePpks\u003c/em\u003e and \u003cem\u003ePbsm42\u003c/em\u003e promoter, respectively. The \u003cem\u003esspD\u003c/em\u003e gene was amplified using primers \u003cem\u003esspD\u003c/em\u003e-F/\u003cem\u003esspD\u003c/em\u003e-R from the genomic DNA of \u003cem\u003eStreptomyces spiramyceticus\u003c/em\u003e\u003cem\u003e.\u003c/em\u003e The \u003cem\u003ePpks\u003c/em\u003e and \u003cem\u003ePbsm42\u003c/em\u003e promoter were amplified using primers \u003cem\u003ePpks\u003c/em\u003e-F/\u003cem\u003ePpks\u003c/em\u003e-R and\u003cem\u003e Pbsm42\u003c/em\u003e-F/\u003cem\u003ePbsm42\u003c/em\u003e-R from the genomic DNA of\u003cem\u003e S. spiramyceticus\u003c/em\u003e 54IA. The fragments containing promoter \u003cem\u003eP\u003c/em\u003e\u003cem\u003epks\u003c/em\u003e or\u003cem\u003e Pbsm42 \u003c/em\u003ewith \u003cem\u003esspD gene\u003c/em\u003e were inserted into the \u003cem\u003eBam\u003c/em\u003eHI/\u003cem\u003eXba\u003c/em\u003eI sites of pSET152 to obtain the resultant plasmids\u003cem\u003e p\u003c/em\u003eSET-\u003cem\u003ePpks\u003c/em\u003e-\u003cem\u003esspD\u003c/em\u003e and pSET-\u003cem\u003ePbsm42\u003c/em\u003e-\u003cem\u003esspD\u003c/em\u003e.\u003c/p\u003e\n\u003cp\u003eTo confirm that the positive regulatory gene \u003cem\u003ebsm23\u003c/em\u003e and \u003cem\u003ebsm42\u003c/em\u003e can improve the carrimycin production，\u003cem\u003ebsm23\u003c/em\u003e and \u003cem\u003ebsm42\u003c/em\u003e were amplified by the primers from the genomic DNA of \u003cem\u003eS\u003c/em\u003e\u003cem\u003e.\u003c/em\u003e\u003cem\u003e spiramyceticus\u003c/em\u003e 54IA, and then inserted into \u003cem\u003eNde\u003c/em\u003eI/\u003cem\u003eXba\u003c/em\u003eI sites of pSET152, under the control of the constitutive promoter\u003cem\u003e kasOp\u003c/em\u003e* to get the plasmids pSET-\u003cem\u003ekasOp\u003c/em\u003e*-bsm23 and pSET-\u003cem\u003ekasOp\u003c/em\u003e*-bsm42 .\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eThe construction of\u003cem\u003e x\u003c/em\u003e\u003c/strong\u003e\u003cstrong\u003e\u003cem\u003eylE\u003c/em\u003e\u003c/strong\u003e\u003cstrong\u003e and \u003cem\u003en\u003c/em\u003e\u003c/strong\u003e\u003cstrong\u003e\u003cem\u003eeo\u003c/em\u003e\u003c/strong\u003e\u003cstrong\u003e double-reporter \u003c/strong\u003e\u003cstrong\u003egenes \u003c/strong\u003e\u003cstrong\u003econtrolled by promoters of \u003cem\u003ebsm42\u003c/em\u003e \u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe promoter of \u003cem\u003ebsm42\u003c/em\u003e could play the indicator for enhanced carrimycin biosynthesis. The 300 bp promoter of \u003cem\u003ebsm42\u003c/em\u003e was amplified by the primer \u003cem\u003ePbsm42\u003c/em\u003e-F1 and \u003cem\u003ePbsm42\u003c/em\u003e-R, and the primer \u003cem\u003ePbsm42\u003c/em\u003e-F2 and \u003cem\u003ePbsm42\u003c/em\u003e-R for the 200 bp length promoter of \u003cem\u003ebsm42\u003c/em\u003e. The two promoter fragments were digested by \u003cem\u003eNot\u003c/em\u003e I, then ligated into the upstream of the two reporter genes \u003cem\u003eneo\u003c/em\u003e (kanamycin resistance gene) and \u003cem\u003exylE\u003c/em\u003e gene at the pDR2 vector to obtain pDR-42F1R and pDR-42F2R plasmids. The \u003cem\u003eneo\u003c/em\u003e was used to ensure the basic selection efficiency while \u003cem\u003exylE\u003c/em\u003e was used to detect target over-expression and visually display the over-expression differences among mutants. The activity of XylE could be detected by spraying catechol on colonies in a selection plate or quantitatively measured in cell-free extract [28]. pDR-42F1R and pDR-42F2R plasmids were individually transduced into the 54IA strain to obtain the resultant strains \u003cem\u003eS. spiramyceticus\u003c/em\u003e F1R and F2R. The 54IA strain containing pDR2 was as the control strain.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003eStreptomyces spiramyceticus\u003c/em\u003e\u003c/strong\u003e\u003cstrong\u003e F\u003c/strong\u003e\u003cstrong\u003e1\u003c/strong\u003e\u003cstrong\u003eR and F\u003c/strong\u003e\u003cstrong\u003e2\u003c/strong\u003e\u003cstrong\u003eR \u003c/strong\u003e\u003cstrong\u003emutated \u003c/strong\u003e\u003cstrong\u003eby UV and plasma\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe lethality rates of \u003cem\u003eS\u003c/em\u003e. \u003cem\u003espiramyceticus \u003c/em\u003eF1R and F2R in five different UV treating times were investigated. After treating for 60, 75 and 90 seconds in the UV, the lethality rates of the F2R spores increase to 74.43%, 79.15%, 95.00% respectively, and the lethality rates of the F1R spores could reach 55.48%, 67.77%, 91.54% respectively. As a result, to obtain the desirable lethality rates the exposure time employed in this study were 75-90 s for F1R and 60-90 s for F2R.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eQuantitative analysis of \u003c/strong\u003e\u003cstrong\u003ecarrrimycin\u003c/strong\u003e\u003cstrong\u003e bioproduction using \u003cem\u003eStreptomyces spiramyceticus \u003c/em\u003e\u003c/strong\u003e\u003cstrong\u003e54IA\u003c/strong\u003e\u003cstrong\u003e and mutant\u003c/strong\u003e\u003cstrong\u003es\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eS\u003c/em\u003e\u003cem\u003e.\u003c/em\u003e\u003cem\u003e spiramyceticus\u003c/em\u003e 54IA and mutants were grown on agar plates for 7 d at 30 \u0026deg;C. The spores were inoculated into 50 mL fermentation medium in an Erlenmeyer flask (250 mL) and incubated at 28\u0026deg;C and 200 rpm for 7 days. To obtain statistically significant results, three independent strains were selected and fermentations were repeated at least three times independently. The resulting fermentation broth was extracted with ethyl acetate (100 mL), and the solvent was removed in vacuum. The extracts were dissolved in 1 mL CH\u003csub\u003e3\u003c/sub\u003eOH and centrifuged at 13,000g for 10 min, and 10 \u0026mu;L of supernatant was subjected to HPLC analysis following the previously described system [15]. In order to calculate the yields of carrimycin in the mutants and the starting strain 54IA, a quantitative curve was established based on the relationship of integral area and the weight of carrimycin. To quantitatively analyze carrimycin titers in the plasmids transduced strains and that of the original strain, extracts of the mutant strains were diluted 10 times and then subjected to HPLC alongside analogously prepared WT-derived extract. The titers of carrimycin in different strains were calculated based on the established standard carrimycin curve. The t-test was used in the quantitative calculation of carrimycin titers in different strains.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTranscriptome analysis and quantitative real-time PCR of \u003c/strong\u003e\u003cstrong\u003e\u003cem\u003es\u003c/em\u003e\u003c/strong\u003e\u003cstrong\u003e\u003cem\u003etreptomyces spiramyceticus \u003c/em\u003e\u003c/strong\u003e\u003cstrong\u003e54IA-2\u003c/strong\u003e \u003cstrong\u003eand mutant strains\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eS. spiramyceticus \u003c/em\u003e54IA and F2R-15 incubated for 120h in soluble fermentation medium were harvested and flash-frozen in liquid N\u003csub\u003e2\u003c/sub\u003e. Frozen mycelia pellets were ground into a fine powder by using a pestle and a mortar, and total RNA was extracted using an RNAprep pure Micro Kit (TIANGEN) according to the manufacturer's instructions. Contaminating chromosomal DNA in the RNA samples was eliminated by treating with DNase I (Promega). The quantity and quality of RNA samples were assessed by measuring the A\u003csub\u003e260\u003c/sub\u003e and A\u003csub\u003e280\u003c/sub\u003e of the samples using Nanodrop (DeNovix), and the integrity of the purified RNA samples was determined by denaturing agarose gel electrophoresis. The transcriptome analysis was performed by OE Biotech (Shanghai, People\u0026rsquo;s Republic China). \u003cem\u003eP\u003c/em\u003e value \u0026lt;0.05 and foldChange \u0026gt;2 set as the threshold for significantly differential expression. Genes with more than 2-fold change and \u003cem\u003eP\u003c/em\u003e value \u0026lt;0.05 were defined as significantly regulated genes.\u003c/p\u003e\n\u003cp\u003eQuantitative real-time PCR was performed on a Light Cycler 96 (Roche) with FastStart Essential DNA Green Master (Roche). All qPCR gene-specific primers were designed to produce \u0026sim;150 bp long amplicons and all reactions were performed in triplicate for three different samples using gene specific primers (Table S3). The 16S RNA gene from \u003cem\u003eS. spiramyceticus\u003c/em\u003e 54IA was used as the internal control to normalize samples. PCR program: 96 \u0026deg;C 1 min (96 \u0026deg;C 30 s, 61 \u0026deg;C 30 s, 72\u0026deg;C 1 min) 40 cycles, 72 \u0026deg;C 10 min. Melting-curve analysis was performed to check the specificity of PCR amplification. Melting-curve analysis was performed to check the specificity of PCR amplification. Cycle threshold (Ct) values were obtained from the exponential phase of PCR amplification and genes expression was normalized against the genes expression of 16S RNA to generate a \u0026Delta;Ct value (Ct of target gene\u0026ndash;Ct of endogenous control). The change in the genes\u0026rsquo; expression was calculated using 2\u003csup\u003e \u0026minus;\u0026Delta;\u0026Delta;Ct\u003c/sup\u003e method.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eStatistics\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eEach experiment was replicated three times, with the error bars showing the standard deviations (SDs). To compare the difference between the test and control data, \u003cem\u003eP\u003c/em\u003e values were calculated by Student\u0026rsquo;s t test (\u003cem\u003eP\u003c/em\u003e \u0026lt; 0.001).\u003c/p\u003e\n\u003cp\u003eThe fragment of \u003cem\u003esco6196\u003c/em\u003e cloned from \u003cem\u003es\u003c/em\u003e\u003cem\u003etreptomyces spiramyceticus \u003c/em\u003e54IA has been deposited in GenBank with the Accession OL616099.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eAcknowledgements\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors acknowledge Prof. Weishan Wang for providing pDR2 plasmid.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAvailability of data and materials\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNot applicable.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eCAMS Innovation Fund for Medical Sciences (2021-1-I2M-028), the National Natural Science Foundation of China (No. 82073900, 81773617), Opening Foundation of State Key Laboratory of Bioactive Substance and Function of Natural Medicines (GTZK202103).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors\u0026rsquo; Contributions\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eWQH and TYH conceived the work and drafted the manuscript. KML and JLD, equally to this study, performed experiments and analyzed data. JJL participated in the experiment and collected the data. TYH and WQH wrote and revised the manuscript. All authors read and approved the final manuscript.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCorrespondent authors\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eCorrespondence to Tianyi Hao or Weiqing He.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEthics approval and consent to participate\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNot applicable\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConsent for publication\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNot applicable.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompeting interest\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors declare that they have no competing interest.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eShang G, Dai J, Wang Y. Construction and physiological studies on a stable bioengineered strain of shengjimycin. J Antibiot (Tokyo). 2001;54:66\u0026ndash;73.\u003c/li\u003e\n\u003cli\u003eEpp JK, Huber ML, Turner JR, Goodson T, Schoner BE. Production of a hybrid macrolide antibiotic in \u003cem\u003eStreptomyces ambofaciens\u003c/em\u003e and \u003cem\u003eStreptomyces lividans\u003c/em\u003e by introduction of a cloned carbomycin biosynthetic gene from \u003cem\u003eStreptomyces thermotolerans\u003c/em\u003e. Gene. 1989;85(2):293\u0026ndash;301.\u003c/li\u003e\n\u003cli\u003eSun CH, Jiang W, Huang J, Jin WZ, Wang YG. Shengjimycins: a group of hybrid antibiotics, 4\u0026rdquo;-acylspiramycins. Actinomycetologica. 1999;13(2):120\u0026ndash;125.\u003c/li\u003e\n\u003cli\u003eShi XG, Sun YM, Zhang YF, Zhong DF. Tissue distribution of bitespiramycin and spiramycin in rats. Acta Pharmacol Sin. 2004;25(11):1396\u0026ndash;401.\u003c/li\u003e\n\u003cli\u003eShi XG, Fawcett JP, Chen XY, Zhong DF. Structural identification of bitespiramycin metabolites in rat: A single oral dose study. Xenobiotica. 2005;35 (4): 343\u0026ndash;358.\u003c/li\u003e\n\u003cli\u003eYan H, Sun J, Wang K, Wang H, Wu S, Bao L, He W, Wang D, Zhu A, Zhang T, Gao R, Dong B, Li J, Yang L, Zhong M, Lv Q, Qin F, Zhuang Z, Huang X, Yang X, Li Y, Che Y, Jiang J.Repurposing CFDA-approved drug carrimycin as an antiviral agent against human coronaviruses, including the currently pandemic SARS-CoV-2. Acta Pharm Sin B. 2021; 11(9):2850\u0026ndash;2858.\u003c/li\u003e\n\u003cli\u003eWang YG, Dai JL, Shang GD. Genetically engineered bacterial strain spiramycin \u003cem\u003estreptomycete\u003c/em\u003e\u003cem\u003espiramyceticus\u003c/em\u003e WSJ-195 of bitespiramycin: CN, 02148771.5. 2004-10-06 (in Chinese).\u003c/li\u003e\n\u003cli\u003eLiu J, Zhang Y, He W. Construction of a novel carrimycin-producing strain by using CRISPR-Cas9 and ribosome engineering techniques. Chin J Biotechnol. 2021; 37(6):2116\u0026ndash;2126.\u003c/li\u003e\n\u003cli\u003eWang HY, Zhou HX, Dai JL, et al. Studies on space-flight breeding of genetically engineered strain of biotechmycin. Chin J Pharm Biotechnol. 2007;14(1):10\u0026ndash;13 (in Chinese).\u003c/li\u003e\n\u003cli\u003eDai JL, Li RF, Wu LZ, et al. Improvement of new generation of bitespiramycin producing strain by microwave radiation. Chin J Antibiot. 2009;34(7): 406\u0026ndash;410, 428 (in Chinese).\u003c/li\u003e\n\u003cli\u003eDai JL, Li RF, WANG YG, WU LZ, He WQ. Optimization of fermentation medium for bitespiramycin production by response surface methodology. Journal of Shenyang Pharmaceutical University. 2010;27(6):482\u0026ndash;488 (in Chinese).\u003c/li\u003e\n\u003cli\u003eLi Z, Wang Y, Chu J, Zhuang Y, Zhang S. Leucine improves the component of isovalerylspiramycins for the production of bitespiramycin. Bioprocess Biosyst Eng. 2009;32:641-647.\u003c/li\u003e\n\u003cli\u003eGao X, Wang Y, Chu J. A preliminary study on the impact of exogenous A-Factor analogue 1,4-butyrolactone on stimulating bitespiramycin biosynthesis. Bioprocess Biosyst Eng. 2019, 42(12):1903\u0026ndash;1913.\u003c/li\u003e\n\u003cli\u003eDai JL, Wang YH, Liu YW, Xiao CY, Tong ZM, Chu J, Zhang SL, Lv GY, Wang YG. Study on the fermentation of genetically engineered strain of biotechmycin in fermentor. Chin J Antibiot. 2005;30(6):324\u0026ndash;327, 428 (in Chinese).\u003c/li\u003e\n\u003cli\u003eLu Z, Zhang X, Dai J, Wang Y, He W. Engineering of leucine-responsive regulatory protein improves spiramycin and bitespiramycin biosynthesis. Microb Cell Fact. 2019;18(1):38.\u003c/li\u003e\n\u003cli\u003eDai JL, Zhang XT, Lu ZL, et al. Breeding of high isomycin-I-producing strain by MPMS composite mutagenesis with plasma and UV. Chin J Antibiot. 2018;43(2):182\u0026ndash;188 (in Chinese).\u003c/li\u003e\n\u003cli\u003eXia H, Zhan X, Mao XM, Li YQ. The regulatory cascades of antibiotic production in Streptomyces. World J Microbiol Biotechnol. 2020;36(1):13.\u003c/li\u003e\n\u003cli\u003eLi L, Wei K, Liu X, Wu Y, Zheng G, Chen S, Jiang W, Lu Y. aMSGE: advanced multiplex site-specific genome engineering withorthogonal modular recombinases in Actinomycetes. Metab Eng. 2019;52:153\u0026ndash;167.\u003c/li\u003e\n\u003cli\u003eYu Z, Lv H, Wu Y, Wei T, Yang S, Ju D, Chen S. Enhancement of FK520 production in \u003cem\u003eStreptomyces hygroscopicus\u003c/em\u003e by combining traditional mutagenesis with metabolic engineering. Appl Microbiol Biotechnol. 2019;103 (23\u0026ndash;24):9593\u0026ndash;9606.\u003c/li\u003e\n\u003cli\u003eXia M, Huang D, Li S, Wen J, Jia X, Chen Y. Enhanced FK506 production in Streptomyces tsukubaensis by rational feeding strategies based on comparative metabolic profiling analysis. Biotechnol Bioeng. 2013;110(10):2717\u0026ndash;2730.\u003c/li\u003e\n\u003cli\u003eWang J, Liu H, Huang D, Jin L, Wang C, Wen J. Comparative proteomic and metabolomic analysis of Streptomyces tsukubaensis reveals the metabolic mechanism of FK506 overproduction by feeding soybean oil. Appl Microbiol Biotechnol. 2017;101(6):2447\u0026ndash;2465.\u003c/li\u003e\n\u003cli\u003eJungWS, Yoo YJ, Park JW, Park SR, Han AR, Ban YH, Kim EJ, Kim E, Yoon YJ. A combined approach of classical mutagenesis and rational metabolic engineering improves rapamycin biosynthesis and provides insights into methylmalonyl-CoA precursor supply pathway in \u003cem\u003eStreptomyces hygroscopicus\u003c/em\u003e ATCC 29253. Appl Microbiol Biotechnol. 2011;91(5):1389\u0026ndash;1397.\u003c/li\u003e\n\u003cli\u003eKarray F, Darbon E, Oestreicher N, Dominguez H, Tuphile K, Gagnat J, Blondelet-Rouault MH, Gerbaud C, Pernodet JL, Organization of the biosynthetic gene cluster for the macrolide antibiotic spiramycin in \u003cem\u003eStreptomyces ambofaciens\u003c/em\u003e. Microbiology. 2007;153:4111\u0026ndash;4122.\u003c/li\u003e\n\u003cli\u003eWang W, Li S, Li Z, Zhang J, Fan K, Tan G, Ai G, Lam SM, Shui G, Yang Z, Lu H, Jin P, Li Y, Chen X, Xia X, Liu X, Dannelly HK, Yang C, Yang Y, Zhang S, Alterovitz G, Xiang W, Zhang L. Harnessing the intracellular triacylglycerols for titer improvement of polyketides in Streptomyces. Nat Biotechnol. 2020;38(1):76\u0026ndash;83.\u003c/li\u003e\n\u003cli\u003eAlvarez HM, Steinbuchel A. Triacylglycerols in prokaryotic microorganisms. Appl Microbiol Biotechnol. 2002;60:367\u0026ndash;376.\u003c/li\u003e\n\u003cli\u003eKarray F, Darbon E, Nguyen HC, Gagnat J, Pernodet JL. Regulation of the biosynthesis of the macrolide antibiotic spiramycin in \u003cem\u003eStreptomyces ambofaciens\u003c/em\u003e. J Bacteriol. 2010;192:5813\u0026ndash;5821.\u003c/li\u003e\n\u003cli\u003eDai J, Wang Y, Liu J, He W. The regulatory genes involved in spiramycin and bitespiramycin biosynthesis. Microbiol Res. 2020;240:126532.\u003c/li\u003e\n\u003cli\u003eXiang SH, Li J, Hua Yin, Zheng JT, Yang X, Wang HB, Luo JL, Bai H, Yang KQ. Application of a double-reporter-guided mutant selection method to improve clavulanic acid production in \u003cem\u003eStreptomyces clavuligerus\u003c/em\u003e. Metab Eng. 2009;11(4-5):310\u0026ndash;318.\u003c/li\u003e\n\u003cli\u003eXia H, Li X, Li Z, Zhan X, Mao X, Li Y. The Application of Regulatory Cascades in Streptomyces: Yield Enhancement and Metabolite Mining. Front Microbiol. 2020;11:406.\u003c/li\u003e\n\u003cli\u003eCundliffe E. Control of tylosin biosynthesis in \u003cem\u003eStreptomyces fradiae\u003c/em\u003e. J Microbiol Biotechnol. 2008;18(9):1485\u0026ndash;1491.\u003c/li\u003e\n\u003cli\u003eXu J, Song Z, Xu X, Ma Z, Bechthold A, Yu X. ToyA, a positive pathway-specific regulator for toyocamycin biosynthesis in \u003cem\u003eStreptomyces diastatochromogenes\u003c/em\u003e Appl Microbiol Biotechnol. 2019;103(17):7071\u0026ndash;7084.\u003c/li\u003e\n\u003cli\u003eZhu Z, Li H, Yu P, Guo Y, Luo S, Chen Z, Mao X, Guan W, Li Y. SlnR is a positive pathway-specific regulator for salinomycin biosynthesis in \u003cem\u003eStreptomyces albus\u003c/em\u003e. Appl Microbiol Biotechnol. 2017;101(4):1547\u0026ndash;1557.\u003c/li\u003e\n\u003cli\u003eZhang Y, He H, Liu H, Wang H, Wang X, Xiang W. Characterization of a pathway-specific activator of milbemycin biosynthesis and improved milbemycin production by its overexpression in \u003cem\u003eStreptomyces bingchenggensis\u003c/em\u003e. Microb Cell Fact. 2016;15(1):152.\u003c/li\u003e\n\u003cli\u003eDai JL, Zhang XT, Lu ZL, et al. Breeding of high isomycin-I-producing strain by MPMS composite mutagenesis with plasma and UV. Chin J Antibiot. 2018;43 (2):182\u0026ndash;188 (in Chinese)\u003c/li\u003e\n\u003cli\u003eWang L, Tian X, Wang J, Yang H, Fan K, Xu G, Yang K, Tan H. Autoregulation of antibiotic biosynthesis by binding of the end product to an atypical response regulator. Proc Natl Acad Sci U S A. 2009;106(21):8617\u0026ndash;8622.\u003c/li\u003e\n\u003cli\u003eLi X, Yu T, He Q, McDowall KJ, Jiang B, Jiang Z, Wu L, Li G, Li Q, Wang S, Shi Y, Wang L, Hong B. Binding of a biosynthetic intermediate to AtrA modulates the production of lidamycin by \u003cem\u003eStreptomyces globisporus\u003c/em\u003e. Mol Microbiol. 2015;96(6):1257\u0026ndash;1271.\u003c/li\u003e\n\u003cli\u003eLei C, Wang J, Liu Y, Liu X, Zhao G, Wang J. A feedback regulatory model for RifQ-mediated repression of rifamycin export in \u003cem\u003eAmycolatopsis mediterranei\u003c/em\u003e. Microb Cell Fact. 2018;17(1):14.\u003c/li\u003e\n\u003cli\u003eMalla S, Niraula NP, Liou K, Sohng JK. Self-resistance mechanism in Streptomyces peucetius: overexpression of \u003cem\u003edrrA\u003c/em\u003e, \u003cem\u003edrrB\u003c/em\u003e and \u003cem\u003edrrC\u003c/em\u003e for doxorubicin enhancement. Microbiol Res. 2010;165(4):259\u0026ndash;267.\u003c/li\u003e\n\u003cli\u003eXia H, Zhan X, Mao XM, Li YQ. The regulatory cascades of antibiotic production in Streptomyces. World J Microbiol Biotechnol. 2020;36(1):13.\u003c/li\u003e\n\u003cli\u003eKieser T, Bibb MJ, Butter MJ, Chater KF, Hopwood DA (2000) Practical Streptomyces genetics: a laboratory manual. The John Innes Foundation, Norwich.\u003c/li\u003e\n\u003cli\u003eWang YG, Jin LF, Jin WZ, Zhang XH, Zeng Y, Xu XM, Jun Y. Cloning and expression of midecamycin 4\u0026rdquo;-acylase gene in spiramycin producing strain. Chin J Biotechnol. 1992;8:1\u0026ndash;14.\u003c/li\u003e\n\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"carrimycin, Streptomyces spiramyceticus 54IA, positive regulator, reporter gene","lastPublishedDoi":"10.21203/rs.3.rs-1204059/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-1204059/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003e\u003cstrong\u003eBackground:\u003c/strong\u003e Carrimycin is a new approved class I antibiotic in China. The novel carrimycin producing strain, \u003cem\u003eStreptomyces spiramyceticus \u003c/em\u003e54IA, was constructed by CRISPR-Cas9 editing system without insertion of antibiotics resistant gene. The problem of low yield limits this strain in large scale fermentation. In this study, the carrimycin production was significantly improved by strain mutagenesis coupled metabolic engineering. \u003c/p\u003e\u003cp\u003e\u003cstrong\u003eResults: \u003c/strong\u003eThe \u003cem\u003esspD\u003c/em\u003e gene is responsible for degradation of triacylglycerol to provide precursors of the polyketide biosynthesis. The extra \u003cem\u003esspD \u003c/em\u003egene controlled by the promoters of \u003cem\u003epks\u003c/em\u003e and \u003cem\u003ebsm42\u003c/em\u003e genes could moderately enhance carrimycin production. The Bsm42 was identified to play a pathway-specific positive regulator for carrimycin biosynthesis. Due to production of carrimycin significantly enhanced by \u003cem\u003ebsm42\u003c/em\u003e overexpression, the two different length promoters of \u003cem\u003ebsm42\u003c/em\u003e individually ligated with two reporter genes were used to monitor \u003cem\u003ebsm42\u003c/em\u003e expression for screening the higher carrimycin production mutants treated by plasma and ultraviolet. 47% of the 608 selected mutants had higher fermentation titer than the starting strain. The shorter promoter of \u003cem\u003ebsm42\u003c/em\u003e displayed more appropriate for selection of the carrimycin production improved mutants. The F2R-15 mutant had highest titer (1010±30 μg/mL), which was about 9 times higher than that of 54IA strain. Comparative analysis of transcriptome profiles of F2R-15 mutant and 54IA strains found 158 differential expression genes with more than 2 fold-changes. The up-regulated genes were associated with macrolide precursor biosynthesis, macrolide-inactivation, antibiotics transporter, oxidative phosphorylation; while the most down-regulated genes were referring to the primary metabolites synthetic genes and biosynthetic genes of other secondary metabolites. \u003c/p\u003e\u003cp\u003e\u003cstrong\u003eConclusion:\u003c/strong\u003e These results suggested that manipulation of the positive regulatory gene \u003cem\u003ebsm42 \u003c/em\u003eand\u003cem\u003e \u003c/em\u003etraditional mutagenesis coupled with reporter-guided mutant selection method facilitated selection of carrimycin high-yielding mutants.\u0026nbsp;\u003c/p\u003e","manuscriptTitle":"Enhancement of Carrimycin Production Via Traditional Mutagenesis with Metabolic Engineering in Streptomyces Spiramyceticus 54IA","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2022-01-14 17:47:46","doi":"10.21203/rs.3.rs-1204059/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"5bef432b-bd32-458d-9b26-9e32c2fcb0eb","owner":[],"postedDate":"January 14th, 2022","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2022-02-19T12:29:10+00:00","versionOfRecord":[],"versionCreatedAt":"2022-01-14 17:47:46","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-1204059","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-1204059","identity":"rs-1204059","version":["v1"]},"buildId":"-HB7Z8yhvgn0wM9Nzuekk","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}